

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
20 March 2003 (20.03.2003)

PCT

(10) International Publication Number  
**WO 03/023004 A2**

(51) International Patent Classification<sup>7</sup>: C12N

(21) International Application Number: PCT/US02/28549

(22) International Filing Date:  
6 September 2002 (06.09.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
09/953,047 10 September 2001 (10.09.2001) US

(71) Applicant: **ISIS PHARMACEUTICALS, INC.**  
[US/US]; 2292 Faraday Avenue, Carlsbad, CA 92008  
(US).

(72) Inventors: **MONIA, Brett, P.**; 7605 Nueva Castilla Way,  
La Costa, CA 92009 (US). **WYATT, Jacqueline, R.**; 1065  
Hymettus Avenue, Encinitas, CA 92024 (US).

(74) Agents: **LICATA, Jane, Massey** et al.; Licata & Tyrrell  
P.C., 66 E. Main Street, Marlton, NJ 08053 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— *without international search report and to be republished upon receipt of that report*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: ANTISENSE MODULATION OF FIBROBLAST GROWTH FACTOR RECEPTOR 3 EXPRESSION

(57) Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of fibroblast growth factor receptor 3. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding fibroblast growth factor receptor 3. Methods of using these compounds for modulation of fibroblast growth factor receptor 3 expression and for treatment of diseases associated with expression of fibroblast growth factor receptor 3 are provided.



WO 03/023004 A2

5 ANTISENSE MODULATION OF FIBROBLAST GROWTH FACTOR RECEPTOR 3  
EXPRESSION

10      **FIELD OF THE INVENTION**

The present invention provides compositions and methods for modulating the expression of fibroblast growth factor receptor 3. In particular, this invention relates to compounds, particularly oligonucleotides, specifically hybridizable with nucleic acids encoding fibroblast growth factor receptor 3. Such compounds have been shown to modulate the expression of fibroblast growth factor receptor 3.

## BACKGROUND OF THE INVENTION

The fibroblast growth factor (FGF) family of signaling polypeptides regulates a diverse array of physiologic functions including mitogenesis, wound healing, cell differentiation and angiogenesis, and development. Both normal and malignant cell growth as well as proliferation are affected by changes in local concentration of these extracellular signaling molecules, which act as autocrine as well as paracrine factors. Autocrine FGF signaling may be particularly important in the progression of steroid hormone-dependent cancers and to a hormone independent state (Powers et al., *Endocr. Relat. Cancer*, 2000, 7, 165-197). FGFs and their receptors are expressed at increased levels in several tissues and cell lines and overexpression is believed to contribute to the malignant phenotype. Furthermore, a number of oncogenes are homologues of genes encoding growth factor receptors, and there is a potential for aberrant activation of FGF-dependent signaling in human pancreatic cancer (Ozawa et al., *Teratog. Carcinog. Mutagen.*, 2001, 21, 27-44).

The two prototypic members are acidic fibroblast growth factor (aFGF or FGF1) and basic fibroblast growth factors (bFGF

-2-

or FGF2), and to date, at least twenty distinct FGF family members have been identified. The cellular response to FGFs is transmitted via four types of high affinity transmembrane tyrosine-kinase fibroblast growth factor receptors numbered 1 to 4 (FGFR-1 to FGFR-4). Upon ligand binding, the receptors dimerize and auto- or trans-phosphorylate specific cytoplasmic tyrosine residues to transmit an intracellular signal that ultimately reaches nuclear transcription factor effectors. Mitogenic signaling by these FGFRs is subsequently mediated via a number of pathways, including the ras/raf/MAP kinase cascade (Ozawa et al., *Teratog. Carcinog. Mutagen.*, 2001, 21, 27-44).

Alternative splicing of the mRNA from the FGFRs 1, 2, and 3 results in a wide range of receptor isoforms with varying ligand-binding properties and specificities. With seven different receptor possibilities and at least 20 ligands in the FGF family, there is a great deal of diversity in the FGF signaling pathway (Powers et al., *Endocr. Relat. Cancer*, 2000, 7, 165-197). Furthermore, expression and localization of the receptor isoforms is regulated in a tissue specific manner. Thus, the various FGFs may exert different influences upon different cell types by interacting with different receptor splice variants to initiate unique intracellular signaling cascades, leading to a panoply of cellular responses (Ozawa et al., *Teratog. Carcinog. Mutagen.*, 2001, 21, 27-44).

Fibroblast growth factor receptor 3 (also known FGF receptor-3, FGFR-3, Fgfr3, ACH, JTK4, and CEK2) was cloned from a cDNA library prepared from human chronic myelogenous leukemia (CML) cells and demonstrated to be a biologically active receptor activated by the acidic and basic fibroblast growth factor family members (Keegan et al., *Proc. Natl. Acad. Sci. U. S. A.*, 1991, 88, 1095-1099).

The human fibroblast growth factor receptor 3 gene was mapped to 4p16.3, in a region displaying significant linkage equilibrium to the Huntington's disease (HD) genetic locus located near the terminus of short arm of human chromosome 4. Fibroblast growth factor receptor 3 was found to be expressed in many areas of the brain, including the caudate and putamen (Thompson et al., *Genomics*, 1991, 11, 1133-1142). The mouse

-3-

Fgfr3 gene was mapped to mouse chromosome 5 in a region of synteny with human chromosome 4 (Avraham et al., *Genomics*, 1994, 21, 656-658).

Disclosed and claimed in PCT Publication WO 01/36632 are the isolated nucleotide sequence of two alternatively spliced variants of fibroblast growth factor receptor 3, as well as sequences complementary to these variants. Also claimed are the amino acid sequences of the two fibroblast growth factor receptor 3 variants, expression vectors comprising the nucleic acid sequences encoding the two variants of fibroblast growth factor receptor 3, a host cell transfected by said expression vector, a pharmaceutical composition comprising a pharmaceutically acceptable carrier and as an active ingredient, said expression vector and the amino acid sequence of fibroblast growth factor receptor 3, and a method for detecting a variant nucleic acid sequence comprising a fibroblast growth factor receptor variant (Levine et al., 2001).

Fibroblast growth factor receptor 3 is involved in long bone development and maintenance, and mutations in fibroblast growth factor receptor 3 have been implicated in skeletal malformations. A Lys644Glu point mutation was introduced into the murine fibroblast growth receptor 3 in a knock-in approach, and this mutation resulted in retarded endochondral bone growth, with the severity of the phenotype linked to the copy number of the mutant allele. Molecular analysis revealed that expression of the mutant receptor ultimately caused the activation of cell cycle inhibitors and led to a dramatic expansion of the resting zone of chondrocytes at the expense of the proliferating chondrocytes. The phenotype of these mice strongly resembled those of human patients with achondroplastic syndromes, characterized by dramatically reduced proliferation of growth plate cartilage, macroencephaly and shortening of the long bones. This mouse model confirms an inhibitory role for fibroblast growth factor receptor 3 in bone growth (Li et al., *Hum. Mol. Genet.*, 1999, 8, 35-44).

More than 75 mutations have been recorded to account for seven skeletal syndromes in humans, and the highest rate of germline point mutations in humans occurs in fibroblast growth

-4-

factor receptors 2 and 3. The most common cause for all the mutant phenotypes is gain-of-function by receptor activation through three major mechanisms: receptor dimerization, kinase activation, and increased affinity for the FGF ligands (Kannan and Givol, *IUBMB Life*, 2000, 49, 197-205).

Specifically, disruptions of fibroblast growth factor receptor 3 signaling are associated with multiple forms of skeletal dysplasias, including achondroplastic (ACH) dwarfism and thanatophoric dysplasia, characterized by short limbs, curved bones and neonatal death as well as hypochondroplasia, less severe than ACH, and Crouzon syndrome, characterized by abnormal ossification of cranial sutures (craniosynostosis) (Kannan and Givol, *IUBMB Life*, 2000, 49, 197-205).

Fibroblast growth factor receptor 3 was shown to exert a negative regulatory effect on bone growth and an inhibition of chondrocyte proliferation. Thanatophoric dysplasia is caused by different mutations in fibroblast growth factor receptor 3, and one mutation, TDII FGFR3, has a constitutive tyrosine kinase activity which activates the transcription factor Stat1, leading to expression of the cell-cycle inhibitor p21<sup>WAF1/CIP1</sup> and growth arrest and abnormal bone development (Su et al., *Nature*, 1997, 386, 288-292).

In contrast to this negative regulation of bone growth, activation of fibroblast growth factor receptor 3 in fibroblasts stimulates proliferation. It appears that fibroblast growth factor receptor 3 signaling can operate along two different pathways, and the Ras-MAPK effector pathway leads to mitogenesis, whereas the STAT1 effector pathway induces cell cycle inhibitors (Kannan and Givol, *IUBMB Life*, 2000, 49, 197-205).

A chromosomal translocation, t(4;14)(p16.3;q32), occurs in 25% of multiple myelomas and lymphoid malignancies, leading to increased expression of fibroblast growth factor receptor 3 and a subset of these tumors also have a mutation which constitutively activates the receptor (Plowright et al., *Blood*, 2000, 95, 992-998; Richelda et al., *Blood*, 1997, 90, 4062-4070). Murine B9 cells transduced with this constitutively activated mutant fibroblast growth factor 3 exhibit enhanced proliferation

-5-

and survival in comparison to controls, indicating an important role for this signaling pathway in tumor development and progression (Plowright et al., *Blood*, 2000, 95, 992-998).

The 4p16.3 chromosomal locus has previously been identified as a region of non-random loss of heterozygosity in transitional cell carcinoma. Analysis of a panel of transitional cell carcinomas and cell lines including bladder, renal, and cervical carcinomas showed that, irrespective of whether the tumor has loss of heterozygosity at the 4p16.3 locus, fibroblast growth factor receptor 3 is frequently mutated. Activating mutations in fibroblast growth factor have now been identified in several cancer types, and it seems likely that these mutations contribute to the malignant phenotype (Sibley et al., *Oncogene*, 2001, 20, 686-691).

A splice variant of the human fibroblast growth factor receptor 3 mRNA, missing exons 7 and 8 which encode the transmembrane domain but bearing an intact kinase domain, has been reported. The gene product of this variant is predicted to be soluble and intracellular, and immunolocalization studies have shown it to be localized to the nucleus in normal breast epithelial cells and in breast cancer cells, but its role in tumorigenesis is not known (Johnston et al., *J. Biol. Chem.*, 1995, 270, 30643-30650).

Finally, in primary colorectal cancer tissues and cell lines, fibroblast growth factor receptor 3 was found to be frequently inactivated by aberrant splicing and usage of cryptic splice donor sites within exon 7 (Jang et al., *Cancer Res.*, 2000, 60, 4049-4052).

The modulation of fibroblast growth factor receptor 3 activity and/or expression is an ideal target for therapeutic intervention aimed at regulating the FGF signaling pathway in the prevention and treatment of many cancers and hyperproliferative diseases.

Investigative strategies aimed at studying fibroblast growth factor receptor 3 localization and function have involved the use of specific antibodies directed against a peptide fragment of fibroblast growth factor receptor 3 (Johnston et

-6-

al., *J. Biol. Chem.*, 1995, 270, 30643-30650) and antisense oligonucleotides.

Disclosed and claimed in PCT Publication WO 00/68424 are methods for detecting carcinomas in a biological sample, comprising identifying fibroblast growth factor receptor 3 mutations using nucleic acid or protein sequences, as well as pharmaceutical preparations having an anti-proliferative effect on carcinoma cells comprising an effective amount of agent(s), including antisense oligonucleotides which act by inhibition of wild type or mutant fibroblast growth factor receptor 3 synthesis or expression (Cappellen et al., 2000).

Currently, there are no known therapeutic agents that effectively inhibit the synthesis of fibroblast growth factor receptor 3. Consequently, there remains a long felt need for agents capable of effectively inhibiting fibroblast growth factor receptor 3 function.

Antisense technology is emerging as an effective means for reducing the expression of specific gene products and therefore may prove to be uniquely useful in a number of therapeutic, diagnostic, and research applications for the modulation of fibroblast growth factor receptor 3 expression.

The present invention provides compositions and methods for modulating fibroblast growth factor receptor 3 expression, including modulation of the truncated mutants and alternatively spliced forms of fibroblast growth factor receptor 3.

#### **SUMMARY OF THE INVENTION**

The present invention is directed to compounds, particularly antisense oligonucleotides, which are targeted to a nucleic acid encoding fibroblast growth factor receptor 3, and which modulate the expression of fibroblast growth factor receptor 3. Pharmaceutical and other compositions comprising the compounds of the invention are also provided. Further provided are methods of modulating the expression of fibroblast growth factor receptor 3 in cells or tissues comprising contacting said cells or tissues with one or more of the antisense compounds or compositions of the invention. Further

-7-

provided are methods of treating an animal, particularly a human, suspected of having or being prone to a disease or condition associated with expression of fibroblast growth factor receptor 3 by administering a therapeutically or

5 prophylactically effective amount of one or more of the antisense compounds or compositions of the invention.

#### DETAILED DESCRIPTION OF THE INVENTION

The present invention employs oligomeric compounds,  
10 particularly antisense oligonucleotides, for use in modulating the function of nucleic acid molecules encoding fibroblast growth factor receptor 3, ultimately modulating the amount of fibroblast growth factor receptor 3 produced. This is accomplished by providing antisense compounds which specifically  
15 hybridize with one or more nucleic acids encoding fibroblast growth factor receptor 3. As used herein, the terms "target nucleic acid" and "nucleic acid encoding fibroblast growth factor receptor 3" encompass DNA encoding fibroblast growth factor receptor 3, RNA (including pre-mRNA and mRNA) transcribed  
20 from such DNA, and also cDNA derived from such RNA. The specific hybridization of an oligomeric compound with its target nucleic acid interferes with the normal function of the nucleic acid. This modulation of function of a target nucleic acid by compounds which specifically hybridize to it is generally  
25 referred to as "antisense". The functions of DNA to be interfered with include replication and transcription. The functions of RNA to be interfered with include all vital functions such as, for example, translocation of the RNA to the site of protein translation, translation of protein from the  
30 RNA, splicing of the RNA to yield one or more mRNA species, and catalytic activity which may be engaged in or facilitated by the RNA. The overall effect of such interference with target nucleic acid function is modulation of the expression of fibroblast growth factor receptor 3. In the context of the  
35 present invention, "modulation" means either an increase (stimulation) or a decrease (inhibition) in the expression of a gene. In the context of the present invention, inhibition is the preferred form of modulation of gene expression and mRNA is

-8-

a preferred target.

It is preferred to target specific nucleic acids for antisense. "Targeting" an antisense compound to a particular nucleic acid, in the context of this invention, is a multistep process. The process usually begins with the identification of a nucleic acid sequence whose function is to be modulated. This may be, for example, a cellular gene (or mRNA transcribed from the gene) whose expression is associated with a particular disorder or disease state, or a nucleic acid molecule from an infectious agent. In the present invention, the target is a nucleic acid molecule encoding fibroblast growth factor receptor 3. The targeting process also includes determination of a site or sites within this gene for the antisense interaction to occur such that the desired effect, e.g., detection or modulation of expression of the protein, will result. Within the context of the present invention, a preferred intragenic site is the region encompassing the translation initiation or termination codon of the open reading frame (ORF) of the gene. Since, as is known in the art, the translation initiation codon is typically 5'-AUG (in transcribed mRNA molecules; 5'-ATG in the corresponding DNA molecule), the translation initiation codon is also referred to as the "AUG codon," the "start codon" or the "AUG start codon". A minority of genes have a translation initiation codon having the RNA sequence 5'-GUG, 5'-UUG or 5'-CUG, and 5'-AUA, 5'-ACG and 5'-CUG have been shown to function in vivo. Thus, the terms "translation initiation codon" and "start codon" can encompass many codon sequences, even though the initiator amino acid in each instance is typically methionine (in eukaryotes) or formylmethionine (in prokaryotes). It is also known in the art that eukaryotic and prokaryotic genes may have two or more alternative start codons, any one of which may be preferentially utilized for translation initiation in a particular cell type or tissue, or under a particular set of conditions. In the context of the invention, "start codon" and "translation initiation codon" refer to the codon or codons that are used in vivo to initiate translation of an mRNA molecule transcribed from a gene encoding fibroblast growth factor receptor 3, regardless of the sequence(s) of such codons.

-9-

It is also known in the art that a translation termination codon (or "stop codon") of a gene may have one of three sequences, i.e., 5'-UAA, 5'-UAG and 5'-UGA (the corresponding DNA sequences are 5'-TAA, 5'-TAG and 5'-TGA, respectively). The terms "start codon region" and "translation initiation codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation initiation codon. Similarly, the terms "stop codon region" and "translation termination codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation termination codon.

The open reading frame (ORF) or "coding region," which is known in the art to refer to the region between the translation initiation codon and the translation termination codon, is also a region which may be targeted effectively. Other target regions include the 5' untranslated region (5'UTR), known in the art to refer to the portion of an mRNA in the 5' direction from the translation initiation codon, and thus including nucleotides between the 5' cap site and the translation initiation codon of an mRNA or corresponding nucleotides on the gene, and the 3' untranslated region (3'UTR), known in the art to refer to the portion of an mRNA in the 3' direction from the translation termination codon, and thus including nucleotides between the translation termination codon and 3' end of an mRNA or corresponding nucleotides on the gene. The 5' cap of an mRNA comprises an N7-methylated guanosine residue joined to the 5'-most residue of the mRNA via a 5'-5' triphosphate linkage. The 5' cap region of an mRNA is considered to include the 5' cap structure itself as well as the first 50 nucleotides adjacent to the cap. The 5' cap region may also be a preferred target region.

Although some eukaryotic mRNA transcripts are directly translated, many contain one or more regions, known as "introns," which are excised from a transcript before it is translated. The remaining (and therefore translated) regions are known as "exons" and are spliced together to form a

-10-

continuous mRNA sequence. mRNA splice sites, i.e., intron-exon junctions, may also be preferred target regions, and are particularly useful in situations where aberrant splicing is implicated in disease, or where an overproduction of a

5 particular mRNA splice product is implicated in disease.

Aberrant fusion junctions due to rearrangements or deletions are also preferred targets. It has also been found that introns can also be effective, and therefore preferred, target regions for antisense compounds targeted, for example, to DNA or pre-mRNA.

10 Once one or more target sites have been identified, oligonucleotides are chosen which are sufficiently complementary to the target, i.e., hybridize sufficiently well and with sufficient specificity, to give the desired effect.

In the context of this invention, "hybridization" means  
15 hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary nucleoside or nucleotide bases. For example, adenine and thymine are complementary nucleobases which pair through the formation of hydrogen bonds. "Complementary," as used herein,  
20 refers to the capacity for precise pairing between two nucleotides. For example, if a nucleotide at a certain position of an oligonucleotide is capable of hydrogen bonding with a nucleotide at the same position of a DNA or RNA molecule, then the oligonucleotide and the DNA or RNA are considered to be  
25 complementary to each other at that position. The oligonucleotide and the DNA or RNA are complementary to each other when a sufficient number of corresponding positions in each molecule are occupied by nucleotides which can hydrogen bond with each other. Thus, "specifically hybridizable" and  
30 "complementary" are terms which are used to indicate a sufficient degree of complementarity or precise pairing such that stable and specific binding occurs between the oligonucleotide and the DNA or RNA target. It is understood in the art that the sequence of an antisense compound need not be  
35 100% complementary to that of its target nucleic acid to be specifically hybridizable. An antisense compound is specifically hybridizable when binding of the compound to the target DNA or RNA molecule interferes with the normal function

-11-

of the target DNA or RNA to cause a loss of utility, and there is a sufficient degree of complementarity to avoid non-specific binding of the antisense compound to non-target sequences under conditions in which specific binding is desired, i.e., under  
5 physiological conditions in the case of in vivo assays or therapeutic treatment, and in the case of in vitro assays, under conditions in which the assays are performed.

Antisense and other compounds of the invention which hybridize to the target and inhibit expression of the target are  
10 identified through experimentation, and the sequences of these compounds are hereinbelow identified as preferred embodiments of the invention. The target sites to which these preferred sequences are complementary are hereinbelow referred to as "active sites" and are therefore preferred sites for targeting.  
15 Therefore another embodiment of the invention encompasses compounds which hybridize to these active sites.

Antisense compounds are commonly used as research reagents and diagnostics. For example, antisense oligonucleotides, which are able to inhibit gene expression with exquisite specificity,  
20 are often used by those of ordinary skill to elucidate the function of particular genes. Antisense compounds are also used, for example, to distinguish between functions of various members of a biological pathway. Antisense modulation has, therefore, been harnessed for research use.

For use in kits and diagnostics, the antisense compounds of the present invention, either alone or in combination with other antisense compounds or therapeutics, can be used as tools in differential and/or combinatorial analyses to elucidate expression patterns of a portion or the entire complement of  
30 genes expressed within cells and tissues.

Expression patterns within cells or tissues treated with one or more antisense compounds are compared to control cells or tissues not treated with antisense compounds and the patterns produced are analyzed for differential levels of gene expression  
35 as they pertain, for example, to disease association, signaling pathway, cellular localization, expression level, size, structure or function of the genes examined. These analyses can be performed on stimulated or unstimulated cells and in the

-12-

presence or absence of other compounds which affect expression patterns.

Examples of methods of gene expression analysis known in the art include DNA arrays or microarrays (Brazma and Vilo, *FEBS Lett.*, **2000**, 480, 17-24; Celis, et al., *FEBS Lett.*, **2000**, 480, 2-16), SAGE (serial analysis of gene expression) (Madden, et al., *Drug Discov. Today*, **2000**, 5, 415-425), READS (restriction enzyme amplification of digested cDNAs) (Prashar and Weissman, *Methods Enzymol.*, **1999**, 303, 258-72), TOGA (total gene expression analysis) (Sutcliffe, et al., *Proc. Natl. Acad. Sci. U. S. A.*, **2000**, 97, 1976-81), protein arrays and proteomics (Celis, et al., *FEBS Lett.*, **2000**, 480, 2-16; Jungblut, et al., *Electrophoresis*, **1999**, 20, 2100-10), expressed sequence tag (EST) sequencing (Celis, et al., *FEBS Lett.*, **2000**, 480, 2-16; Larsson, et al., *J. Biotechnol.*, **2000**, 80, 143-57), subtractive RNA fingerprinting (SuRF) (Fuchs, et al., *Anal. Biochem.*, **2000**, 286, 91-98; Larson, et al., *Cytometry*, **2000**, 41, 203-208), subtractive cloning, differential display (DD) (Jurecic and Belmont, *Curr. Opin. Microbiol.*, **2000**, 3, 316-21), comparative genomic hybridization (Carulli, et al., *J. Cell Biochem. Suppl.*, **1998**, 31, 286-96), FISH (fluorescent in situ hybridization) techniques (Going and Gusterson, *Eur. J. Cancer*, **1999**, 35, 1895-904) and mass spectrometry methods (reviewed in (To, *Comb. Chem. High Throughput Screen*, **2000**, 3, 235-41).

The specificity and sensitivity of antisense is also harnessed by those of skill in the art for therapeutic uses. Antisense oligonucleotides have been employed as therapeutic moieties in the treatment of disease states in animals and man. Antisense oligonucleotide drugs, including ribozymes, have been safely and effectively administered to humans and numerous clinical trials are presently underway. It is thus established that oligonucleotides can be useful therapeutic modalities that can be configured to be useful in treatment regimes for treatment of cells, tissues and animals, especially humans.

In the context of this invention, the term "oligonucleotide" refers to an oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or mimetics thereof. This term includes oligonucleotides composed

-13-

of naturally-occurring nucleobases, sugars and covalent internucleoside (backbone) linkages as well as oligonucleotides having non-naturally-occurring portions which function similarly. Such modified or substituted oligonucleotides are often preferred over native forms because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for nucleic acid target and increased stability in the presence of nucleases.

While antisense oligonucleotides are a preferred form of antisense compound, the present invention comprehends other oligomeric antisense compounds, including but not limited to oligonucleotide mimetics such as are described below. The antisense compounds in accordance with this invention preferably comprise from about 8 to about 50 nucleobases (i.e. from about 8 to about 50 linked nucleosides). Particularly preferred antisense compounds are antisense oligonucleotides, even more preferably those comprising from about 12 to about 30 nucleobases. Antisense compounds include ribozymes, external guide sequence (EGS) oligonucleotides (oligozymes), and other short catalytic RNAs or catalytic oligonucleotides which hybridize to the target nucleic acid and modulate its expression.

As is known in the art, a nucleoside is a base-sugar combination. The base portion of the nucleoside is normally a heterocyclic base. The two most common classes of such heterocyclic bases are the purines and the pyrimidines. Nucleotides are nucleosides that further include a phosphate group covalently linked to the sugar portion of the nucleoside. For those nucleosides that include a pentofuranosyl sugar, the phosphate group can be linked to either the 2', 3' or 5' hydroxyl moiety of the sugar. In forming oligonucleotides, the phosphate groups covalently link adjacent nucleosides to one another to form a linear polymeric compound. In turn the respective ends of this linear polymeric structure can be further joined to form a circular structure, however, open linear structures are generally preferred. Within the oligonucleotide structure, the phosphate groups are commonly referred to as forming the internucleoside backbone of the

-14-

oligonucleotide. The normal linkage or backbone of RNA and DNA is a 3' to 5' phosphodiester linkage.

Specific examples of preferred antisense compounds useful in this invention include oligonucleotides containing modified  
5 backbones or non-natural internucleoside linkages. As defined in this specification, oligonucleotides having modified backbones include those that retain a phosphorus atom in the backbone and those that do not have a phosphorus atom in the backbone. For the purposes of this specification, and as  
10 sometimes referenced in the art, modified oligonucleotides that do not have a phosphorus atom in their internucleoside backbone can also be considered to be oligonucleosides.

Preferred modified oligonucleotide backbones include, for example, phosphorothioates, chiral phosphorothioates, phosphoro-  
15 dithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates, 5'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkyl-  
20 phosphonates, thionoalkylphosphotriesters, selenophosphates and boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein one or more internucleotide linkages is a 3' to 3', 5' to 5' or 2' to 2' linkage. Preferred oligonucleotides having inverted  
25 polarity comprise a single 3' to 3' linkage at the 3'-most internucleotide linkage i.e. a single inverted nucleoside residue which may be abasic (the nucleobase is missing or has a hydroxyl group in place thereof). Various salts, mixed salts and free acid forms are also included.

30 Representative United States patents that teach the preparation of the above phosphorus-containing linkages include, but are not limited to, U.S.: 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939;  
35 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; 5,194,599; 5,565,555; 5,527,899; 5,721,218; 5,672,697 and 5,625,050, certain of which are commonly owned with this

-15-

application, and each of which is herein incorporated by reference.

Preferred modified oligonucleotide backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; riboacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH<sub>2</sub> component parts.

Representative United States patents that teach the preparation of the above oligonucleosides include, but are not limited to, U.S.: 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; 5,792,608; 5,646,269 and 5,677,439, certain of which are commonly owned with this application, and each of which is herein incorporated by reference.

In other preferred oligonucleotide mimetics, both the sugar and the internucleoside linkage, i.e., the backbone, of the nucleotide units are replaced with novel groups. The base units are maintained for hybridization with an appropriate nucleic acid target compound. One such oligomeric compound, an oligonucleotide mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar-backbone of an oligonucleotide is replaced with an amide containing backbone, in particular an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone.

-16-

Representative United States patents that teach the preparation of PNA compounds include, but are not limited to, U.S.:

5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference. Further teaching of PNA compounds can be found in Nielsen et al., *Science*, **1991**, 254, 1497-1500.

Most preferred embodiments of the invention are oligonucleotides with phosphorothioate backbones and oligonucleosides with heteroatom backbones, and in particular -CH<sub>2</sub>-NH-O-CH<sub>2</sub>-, -CH<sub>2</sub>-N(CH<sub>3</sub>)-O-CH<sub>2</sub>- [known as a methylene (methylimino) or MMI backbone], -CH<sub>2</sub>-O-N(CH<sub>3</sub>)-CH<sub>2</sub>-, -CH<sub>2</sub>-N(CH<sub>3</sub>)-N(CH<sub>3</sub>)-CH<sub>2</sub>- and -O-N(CH<sub>3</sub>)-CH<sub>2</sub>-CH<sub>2</sub>- [wherein the native phosphodiester backbone is represented as -O-P-O-CH<sub>2</sub>-] of the above referenced U.S. patent 5,489,677, and the amide backbones of the above referenced U.S. patent 5,602,240. Also preferred are oligonucleotides having morpholino backbone structures of the above-referenced U.S. patent 5,034,506.

Modified oligonucleotides may also contain one or more substituted sugar moieties. Preferred oligonucleotides comprise one of the following at the 2' position: OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted C<sub>1</sub> to C<sub>10</sub> alkyl or C<sub>2</sub> to C<sub>10</sub> alkenyl and alkynyl. Particularly preferred are O[(CH<sub>2</sub>)<sub>n</sub>O]<sub>m</sub>CH<sub>3</sub>, O(CH<sub>2</sub>)<sub>n</sub>OCH<sub>3</sub>, O(CH<sub>2</sub>)<sub>n</sub>NH<sub>2</sub>, O(CH<sub>2</sub>)<sub>n</sub>CH<sub>3</sub>, O(CH<sub>2</sub>)<sub>n</sub>ONH<sub>2</sub>, and O(CH<sub>2</sub>)<sub>n</sub>ON[(CH<sub>2</sub>)<sub>n</sub>CH<sub>3</sub>]<sub>2</sub>, where n and m are from 1 to about 10. Other preferred oligonucleotides comprise one of the following at the 2' position: C<sub>1</sub> to C<sub>10</sub> lower alkyl, substituted lower alkyl, alkenyl, alkynyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH<sub>3</sub>, OCN, Cl, Br, CN, CF<sub>3</sub>, OCF<sub>3</sub>, SOCH<sub>3</sub>, SO<sub>2</sub>CH<sub>3</sub>, ONO<sub>2</sub>, NO<sub>2</sub>, N<sub>3</sub>, NH<sub>2</sub>, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties. A preferred modification includes 2'-methoxyethoxy (2'-O-CH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub>, also known as 2'-O-(2-methoxyethyl) or 2'-MOE) (Martin et al., *Helv. Chim. Acta*, **1995**, 78, 486-504) i.e., an alkoxyalkoxy group. A further preferred modification includes

-17-

2'-dimethylaminoethoxyethoxy, i.e., a  $O(CH_2)_2ON(CH_3)_2$  group, also known as 2'-DMAOE, as described in examples hereinbelow, and 2'-dimethylaminoethoxyethoxy (also known in the art as 2'-O-dimethylaminoethoxyethyl or 2'-DMAEOE), i.e., 2'-O-CH<sub>2</sub>-O-CH<sub>2</sub>-N(CH<sub>3</sub>)<sub>2</sub>, also described in examples hereinbelow.

A further preferred modification includes Locked Nucleic Acids (LNAs) in which the 2'-hydroxyl group is linked to the 3' or 4' carbon atom of the sugar ring thereby forming a bicyclic sugar moiety. The linkage is preferably a methylene (-CH<sub>2</sub>-)<sub>n</sub> group bridging the 2' oxygen atom and the 4' carbon atom wherein n is 1 or 2. LNAs and preparation thereof are described in WO 98/39352 and WO 99/14226.

Other preferred modifications include 2'-methoxy (2'-O-CH<sub>3</sub>), 2'-aminopropoxy (2'-OCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>), 2'-allyl (2'-CH<sub>2</sub>-CH=CH<sub>2</sub>), 2'-O-allyl (2'-O-CH<sub>2</sub>-CH=CH<sub>2</sub>) and 2'-fluoro (2'-F). The 2'-modification may be in the arabino (up) position or ribo (down) position. A preferred 2'-arabino modification is 2'-F. Similar modifications may also be made at other positions on the oligonucleotide, particularly the 3' position of the sugar on the 3' terminal nucleotide or in 2'-5' linked oligonucleotides and the 5' position of 5' terminal nucleotide. Oligonucleotides may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar. Representative United States patents that teach the preparation of such modified sugar structures include, but are not limited to, U.S.: 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633; 5,792,747; and 5,700,920, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference in its entirety.

Oligonucleotides may also include nucleobase (often referred to in the art simply as "base") modifications or substitutions. As used herein, "unmodified" or "natural" nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified nucleobases include other synthetic and

-18-

natural nucleobases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl ( $-C\equiv C-CH_3$ ) uracil and cytosine and other alkynyl derivatives of pyrimidine bases, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 2-F-adenine, 2-amino-adenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine. Further modified nucleobases include tricyclic pyrimidines such as phenoxazine cytidine (1H-pyrimido[5,4-b][1,4]benzoxazin-2(3H)-one), phenothiazine cytidine (1H-pyrimido[5,4-b][1,4]benzothiazin-2(3H)-one), G-clamps such as a substituted phenoxazine cytidine (e.g. 9-(2-aminoethoxy)-H-pyrimido[5,4-b][1,4]benzoxazin-2(3H)-one), carbazole cytidine (2H-pyrimido[4,5-b]indol-2-one), pyridoindole cytidine (H-pyrido[3',2':4,5]pyrrolo[2,3-d]pyrimidin-2-one). Modified nucleobases may also include those in which the purine or pyrimidine base is replaced with other heterocycles, for example 7-deaza-adenine, 7-deazaguanosine, 2-aminopyridine and 2-pyridone. Further nucleobases include those disclosed in United States Patent No. 3,687,808, those disclosed in *The Concise Encyclopedia Of Polymer Science And Engineering*, pages 858-859, Kroschwitz, J.I., ed. John Wiley & Sons, **1990**, those disclosed by Englisch et al., *Angewandte Chemie*, International Edition, **1991**, 30, 613, and those disclosed by Sanghvi, Y.S., Chapter 15, *Antisense Research and Applications*, pages 289-302, Crooke, S.T. and Lebleu, B., ed., CRC Press, **1993**. Certain of these nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds of the invention. These include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine

-19-

substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2°C (Sanghvi, Y.S., Crooke, S.T. and Lebleu, B., eds., *Antisense Research and Applications*, CRC Press, Boca Raton, **1993**, pp. 276-278) and are presently preferred base  
5 substitutions, even more particularly when combined with 2'-O-methoxyethyl sugar modifications.

Representative United States patents that teach the preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include, but are not  
10 limited to, the above noted U.S. 3,687,808, as well as U.S.:  
4,845,205; 5,130,302; 5,134,066; 5,175,273; 5,367,066;  
5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177;  
5,525,711; 5,552,540; 5,587,469; 5,594,121, 5,596,091;  
5,614,617; 5,645,985; 5,830,653; 5,763,588; 6,005,096; and  
15 5,681,941, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference, and United States patent 5,750,692, which is commonly owned with the instant application and also herein incorporated by reference.

20 Another modification of the oligonucleotides of the invention involves chemically linking to the oligonucleotide one or more moieties or conjugates which enhance the activity, cellular distribution or cellular uptake of the oligonucleotide. The compounds of the invention can include conjugate groups  
25 covalently bound to functional groups such as primary or secondary hydroxyl groups. Conjugate groups of the invention include intercalators, reporter molecules, polyamines, polyamides, polyethylene glycols, polyethers, groups that enhance the pharmacodynamic properties of oligomers, and groups  
30 that enhance the pharmacokinetic properties of oligomers. Typical conjugates groups include cholesterols, lipids, phospholipids, biotin, phenazine, folate, phenanthridine, anthraquinone, acridine, fluoresceins, rhodamines, coumarins, and dyes. Groups that enhance the pharmacodynamic properties, in  
35 the context of this invention, include groups that improve oligomer uptake, enhance oligomer resistance to degradation, and/or strengthen sequence-specific hybridization with RNA. Groups that enhance the pharmacokinetic properties, in the

-20-

context of this invention, include groups that improve oligomer uptake, distribution, metabolism or excretion. Representative conjugate groups are disclosed in International Patent Application PCT/US92/09196, filed October 23, 1992 the entire disclosure of which is incorporated herein by reference. Conjugate moieties include but are not limited to lipid moieties such as a cholesterol moiety (Letsinger et al., *Proc. Natl. Acad. Sci. USA*, **1989**, 86, 6553-6556), cholic acid (Manoharan et al., *Bioorg. Med. Chem. Lett.*, **1994**, 4, 1053-1060), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., *Ann. N.Y. Acad. Sci.*, **1992**, 660, 306-309; Manoharan et al., *Bioorg. Med. Chem. Lett.*, **1993**, 3, 2765-2770), a thiocholesterol (Oberhauser et al., *Nucl. Acids Res.*, **1992**, 20, 533-538), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al., *EMBO J.*, **1991**, 10, 1111-1118; Kabanov et al., *FEBS Lett.*, **1990**, 259, 327-330; Svinarchuk et al., *Biochimie*, **1993**, 75, 49-54), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethyl-ammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., *Tetrahedron Lett.*, **1995**, 36, 3651-3654; Shea et al., *Nucl. Acids Res.*, **1990**, 18, 3777-3783), a polyamine or a polyethylene glycol chain (Manoharan et al., *Nucleosides & Nucleotides*, **1995**, 14, 969-973), or adamantane acetic acid (Manoharan et al., *Tetrahedron Lett.*, **1995**, 36, 3651-3654), a palmityl moiety (Mishra et al., *Biochim. Biophys. Acta*, **1995**, 1264, 229-237), or an octadecylamine or hexylamino-carbonyloxycholesterol moiety (Crooke et al., *J. Pharmacol. Exp. Ther.*, **1996**, 277, 923-937. Oligonucleotides of the invention may also be conjugated to active drug substances, for example, aspirin, warfarin, phenylbutazone, ibuprofen, suprofen, fenbufen, ketoprofen, (S)-(+)-pranoprofen, carprofen, dansylsarcosine, 2,3,5-triiodobenzoic acid, flufenamic acid, folinic acid, a benzothiadiazide, chlorothiazide, a diazepine, indomethicin, a barbiturate, a cephalosporin, a sulfa drug, an antidiabetic, an antibacterial or an antibiotic. Oligonucleotide-drug conjugates and their preparation are described in United States Patent Application 09/334,130 (filed June 15, 1999) which is incorporated herein by reference in its entirety.

Representative United States patents that teach the

-21-

preparation of such oligonucleotide conjugates include, but are not limited to, U.S.: 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717, 5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 10 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241, 5,391,723; 5,416,203, 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and 5,688,941, certain of which are commonly owned with the instant 15 application, and each of which is herein incorporated by reference.

It is not necessary for all positions in a given compound to be uniformly modified, and in fact more than one of the aforementioned modifications may be incorporated in a single 20 compound or even at a single nucleoside within an oligonucleotide. The present invention also includes antisense compounds which are chimeric compounds. "Chimeric" antisense compounds or "chimeras," in the context of this invention, are antisense compounds, particularly oligonucleotides, which 25 contain two or more chemically distinct regions, each made up of at least one monomer unit, i.e., a nucleotide in the case of an oligonucleotide compound. These oligonucleotides typically contain at least one region wherein the oligonucleotide is modified so as to confer upon the oligonucleotide increased 30 resistance to nuclease degradation, increased cellular uptake, and/or increased binding affinity for the target nucleic acid. An additional region of the oligonucleotide may serve as a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. By way of example, RNase H is a cellular endonuclease 35 which cleaves the RNA strand of an RNA:DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of oligonucleotide inhibition of gene expression. Consequently, comparable results

-22-

can often be obtained with shorter oligonucleotides when chimeric oligonucleotides are used, compared to phosphorothioate deoxyoligonucleotides hybridizing to the same target region. Cleavage of the RNA target can be routinely detected by gel  
5 electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art.

Chimeric antisense compounds of the invention may be formed as composite structures of two or more oligonucleotides, modified oligonucleotides, oligonucleosides and/or  
10 oligonucleotide mimetics as described above. Such compounds have also been referred to in the art as hybrids or gapmers. Representative United States patents that teach the preparation of such hybrid structures include, but are not limited to, U.S.: 5,013,830; 5,149,797; 5,220,007; 5,256,775; 5,366,878;  
15 5,403,711; 5,491,133; 5,565,350; 5,623,065; 5,652,355; 5,652,356; and 5,700,922, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference in its entirety.

The antisense compounds used in accordance with this  
20 invention may be conveniently and routinely made through the well-known technique of solid phase synthesis. Equipment for such synthesis is sold by several vendors including, for example, Applied Biosystems (Foster City, CA). Any other means for such synthesis known in the art may additionally or  
25 alternatively be employed. It is well known to use similar techniques to prepare oligonucleotides such as the phosphorothioates and alkylated derivatives.

The antisense compounds of the invention are synthesized in vitro and do not include antisense compositions of biological  
30 origin, or genetic vector constructs designed to direct the in vivo synthesis of antisense molecules.

The compounds of the invention may also be admixed, encapsulated, conjugated or otherwise associated with other molecules, molecule structures or mixtures of compounds, as for  
35 example, liposomes, receptor targeted molecules, oral, rectal, topical or other formulations, for assisting in uptake, distribution and/or absorption. Representative United States patents that teach the preparation of such uptake, distribution

-23-

and/or absorption assisting formulations include, but are not limited to, U.S.: 5,108,921; 5,354,844; 5,416,016; 5,459,127; 5,521,291; 5,543,158; 5,547,932; 5,583,020; 5,591,721; 4,426,330; 4,534,899; 5,013,556; 5,108,921; 5,213,804; 5,227,170; 5,264,221; 5,356,633; 5,395,619; 5,416,016; 5,417,978; 5,462,854; 5,469,854; 5,512,295; 5,527,528; 5,534,259; 5,543,152; 5,556,948; 5,580,575; and 5,595,756, each of which is herein incorporated by reference.

The antisense compounds of the invention encompass any pharmaceutically acceptable salts, esters, or salts of such esters, or any other compound which, upon administration to an animal including a human, is capable of providing (directly or indirectly) the biologically active metabolite or residue thereof. Accordingly, for example, the disclosure is also drawn to prodrugs and pharmaceutically acceptable salts of the compounds of the invention, pharmaceutically acceptable salts of such prodrugs, and other bioequivalents.

The term "prodrug" indicates a therapeutic agent that is prepared in an inactive form that is converted to an active form (i.e., drug) within the body or cells thereof by the action of endogenous enzymes or other chemicals and/or conditions. In particular, prodrug versions of the oligonucleotides of the invention are prepared as SATE [(S-acetyl-2-thioethyl) phosphate] derivatives according to the methods disclosed in WO 93/24510 to Gosselin et al., published December 9, 1993 or in WO 94/26764 and U.S. 5,770,713 to Imbach et al.

The term "pharmaceutically acceptable salts" refers to physiologically and pharmaceutically acceptable salts of the compounds of the invention: i.e., salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects thereto.

Pharmaceutically acceptable base addition salts are formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Examples of metals used as cations are sodium, potassium, magnesium, calcium, and the like. Examples of suitable amines are N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine (see, for

-24-

example, Berge et al., "Pharmaceutical Salts," *J. of Pharma Sci.*, **1977**, 66, 1-19). The base addition salts of said acidic compounds are prepared by contacting the free acid form with a sufficient amount of the desired base to produce the salt in the conventional manner. The free acid form may be regenerated by contacting the salt form with an acid and isolating the free acid in the conventional manner. The free acid forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free acid for purposes of the present invention. As used herein, a "pharmaceutical addition salt" includes a pharmaceutically acceptable salt of an acid form of one of the components of the compositions of the invention. These include organic or inorganic acid salts of the amines. Preferred acid salts are the hydrochlorides, acetates, salicylates, nitrates and phosphates. Other suitable pharmaceutically acceptable salts are well known to those skilled in the art and include basic salts of a variety of inorganic and organic acids, such as, for example, with inorganic acids, such as for example hydrochloric acid, hydrobromic acid, sulfuric acid or phosphoric acid; with organic carboxylic, sulfonic, sulfo or phospho acids or N-substituted sulfamic acids, for example acetic acid, propionic acid, glycolic acid, succinic acid, maleic acid, hydroxymaleic acid, methylmaleic acid, fumaric acid, malic acid, tartaric acid, lactic acid, oxalic acid, gluconic acid, glucaric acid, glucuronic acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, salicylic acid, 4-aminosalicylic acid, 2-phenoxybenzoic acid, 2-acetoxybenzoic acid, embonic acid, nicotinic acid or isonicotinic acid; and with amino acids, such as the 20 alpha-amino acids involved in the synthesis of proteins in nature, for example glutamic acid or aspartic acid, and also with phenylacetic acid, methanesulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, ethane-1,2-disulfonic acid, benzenesulfonic acid, 4-methylbenzenesulfonic acid, naphthalene-2-sulfonic acid, naphthalene-1,5-disulfonic acid, 2- or 3-phosphoglycerate, glucose-6-phosphate, N-cyclohexylsulfamic acid (with the

-25-

formation of cyclamates), or with other acid organic compounds, such as ascorbic acid. Pharmaceutically acceptable salts of compounds may also be prepared with a pharmaceutically acceptable cation. Suitable pharmaceutically acceptable cations are well known to those skilled in the art and include alkaline, alkaline earth, ammonium and quaternary ammonium cations. Carbonates or hydrogen carbonates are also possible.

For oligonucleotides, preferred examples of pharmaceutically acceptable salts include but are not limited to

(a) salts formed with cations such as sodium, potassium, ammonium, magnesium, calcium, polyamines such as spermine and spermidine, etc.; (b) acid addition salts formed with inorganic acids, for example hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the like; (c) salts formed with organic acids such as, for example, acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid, palmitic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acid, polygalacturonic acid, and the like; and (d) salts formed from elemental anions such as chlorine, bromine, and iodine.

The antisense compounds of the present invention can be utilized for diagnostics, therapeutics, prophylaxis and as research reagents and kits. For therapeutics, an animal, preferably a human, suspected of having a disease or disorder which can be treated by modulating the expression of fibroblast growth factor receptor 3 is treated by administering antisense compounds in accordance with this invention. The compounds of the invention can be utilized in pharmaceutical compositions by adding an effective amount of an antisense compound to a suitable pharmaceutically acceptable diluent or carrier. Use of the antisense compounds and methods of the invention may also be useful prophylactically, e.g., to prevent or delay infection, inflammation or tumor formation, for example.

The antisense compounds of the invention are useful for research and diagnostics, because these compounds hybridize to nucleic acids encoding fibroblast growth factor receptor 3,

-26-

enabling sandwich and other assays to easily be constructed to exploit this fact. Hybridization of the antisense oligonucleotides of the invention with a nucleic acid encoding fibroblast growth factor receptor 3 can be detected by means known in the art. Such means may include conjugation of an enzyme to the oligonucleotide, radiolabelling of the oligonucleotide or any other suitable detection means. Kits using such detection means for detecting the level of fibroblast growth factor receptor 3 in a sample may also be prepared.

The present invention also includes pharmaceutical compositions and formulations which include the antisense compounds of the invention. The pharmaceutical compositions of the present invention may be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic and to mucous membranes including vaginal and rectal delivery), pulmonary, e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal), oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration. Oligonucleotides with at least one 2'-O-methoxyethyl modification are believed to be particularly useful for oral administration.

Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable. Coated condoms, gloves and the like may also be useful. Preferred topical formulations include those in which the oligonucleotides of the invention are in admixture with a topical delivery agent such as lipids, liposomes, fatty acids, fatty acid esters, steroids, chelating agents and surfactants. Preferred lipids and liposomes include neutral (e.g. dioleoylphosphatidyl DOPE ethanolamine, dimyristoylphosphatidyl choline DMPC, distearoylphosphatidyl choline) negative (e.g.

-27-

dimyristoylphosphatidyl glycerol DMPG) and cationic (e.g. dioleoyltetramethylaminopropyl DOTAP and dioleoylphosphatidyl ethanolamine DOTMA). Oligonucleotides of the invention may be encapsulated within liposomes or may form complexes thereto, in particular to cationic liposomes. Alternatively, oligonucleotides may be complexed to lipids, in particular to cationic lipids. Preferred fatty acids and esters include but are not limited arachidonic acid, oleic acid, eicosanoic acid, lauric acid, caprylic acid, capric acid, myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, monoolein, dilaurin, glyceryl 1-monocaprate, 1-dodecylazacycloheptan-2-one, an acylcarnitine, an acylcholine, or a C<sub>1-10</sub> alkyl ester (e.g. isopropylmyristate IPM), monoglyceride, diglyceride or pharmaceutically acceptable salt thereof. Topical formulations are described in detail in United States patent application 09/315,298 filed on May 20, 1999 which is incorporated herein by reference in its entirety.

Compositions and formulations for oral administration include powders or granules, microparticulates, nanoparticulates, suspensions or solutions in water or non-aqueous media, capsules, gel capsules, sachets, tablets or minitables. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders may be desirable. Preferred oral formulations are those in which oligonucleotides of the invention are administered in conjunction with one or more penetration enhancers surfactants and chelators. Preferred surfactants include fatty acids and/or esters or salts thereof, bile acids and/or salts thereof. Preferred bile acids/salts include chenodeoxycholic acid (CDCA) and ursodeoxychenodeoxycholic acid (UDCA), cholic acid, dehydrocholic acid, deoxycholic acid, glucolic acid, glycholic acid, glycodeoxycholic acid, taurocholic acid, taurodeoxycholic acid, sodium tauro-24,25-dihydro-fusidate, sodium glycodihydrofusidate,. Preferred fatty acids include arachidonic acid, undecanoic acid, oleic acid, lauric acid, caprylic acid, capric acid, myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, monoolein, dilaurin, glyceryl 1-monocaprate, 1-dodecylazacycloheptan-2-one,

-28-

an acylcarnitine, an acylcholine, or a monoglyceride, a diglyceride or a pharmaceutically acceptable salt thereof (e.g. sodium). Also preferred are combinations of penetration enhancers, for example, fatty acids/salts in combination with bile acids/salts. A particularly preferred combination is the sodium salt of lauric acid, capric acid and UDCA. Further penetration enhancers include polyoxyethylene-9-lauryl ether, polyoxyethylene-20-cetyl ether. Oligonucleotides of the invention may be delivered orally in granular form including sprayed dried particles, or complexed to form micro or nanoparticles. Oligonucleotide complexing agents include poly-amino acids; polyimines; polyacrylates; polyalkylacrylates, polyoxethanes, polyalkylcyanoacrylates; cationized gelatins, albumins, starches, acrylates, polyethyleneglycols (PEG) and starches; polyalkylcyanoacrylates; DEAE-derivatized polyimines, pollulans, celluloses and starches. Particularly preferred complexing agents include chitosan, N-trimethylchitosan, poly-L-lysine, polyhistidine, polyornithine, polyspermines, protamine, polyvinylpyridine, polythiodiethylamino-methylethylene P(TDAE), polyaminostyrene (e.g. p-amino), poly(methylcyanoacrylate), poly(ethylcyanoacrylate), poly(butylcyanoacrylate), poly(isobutylcyanoacrylate), poly(isohexylcyanoacrylate), DEAE-methacrylate, DEAE-hexylacrylate, DEAE-acrylamide, DEAE-albumin and DEAE-dextran, polymethylacrylate, polyhexylacrylate, poly(D,L-lactic acid), poly(DL-lactic-co-glycolic acid (PLGA), alginate, and polyethyleneglycol (PEG). Oral formulations for oligonucleotides and their preparation are described in detail in United States applications 08/886,829 (filed July 1, 1997), 09/108,673 (filed July 1, 1998), 09/256,515 (filed February 23, 1999), 09/082,624 (filed May 21, 1998) and 09/315,298 (filed May 20, 1999) each of which is incorporated herein by reference in their entirety.

Compositions and formulations for parenteral, intrathecal or intraventricular administration may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives such as, but not limited to, penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients.

-29-

Pharmaceutical compositions of the present invention include, but are not limited to, solutions, emulsions, and liposome-containing formulations. These compositions may be generated from a variety of components that include, but are not limited to, preformed liquids, self-emulsifying solids and self-emulsifying semisolids.

The pharmaceutical formulations of the present invention, which may conveniently be presented in unit dosage form, may be prepared according to conventional techniques well known in the pharmaceutical industry. Such techniques include the step of bringing into association the active ingredients with the pharmaceutical carrier(s) or excipient(s). In general the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

The compositions of the present invention may be formulated into any of many possible dosage forms such as, but not limited to, tablets, capsules, gel capsules, liquid syrups, soft gels, suppositories, and enemas. The compositions of the present invention may also be formulated as suspensions in aqueous, non-aqueous or mixed media. Aqueous suspensions may further contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

In one embodiment of the present invention the pharmaceutical compositions may be formulated and used as foams. Pharmaceutical foams include formulations such as, but not limited to, emulsions, microemulsions, creams, jellies and liposomes. While basically similar in nature these formulations vary in the components and the consistency of the final product. The preparation of such compositions and formulations is generally known to those skilled in the pharmaceutical and formulation arts and may be applied to the formulation of the compositions of the present invention.

-30-

## Emulsions

The compositions of the present invention may be prepared and formulated as emulsions. Emulsions are typically heterogenous systems of one liquid dispersed in another in the form of droplets usually exceeding 0.1  $\mu\text{m}$  in diameter. (Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), **1988**, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199; Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), **1988**, Marcel Dekker, Inc., New York, N.Y., Volume 1, p. 245; Block in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), **1988**, Marcel Dekker, Inc., New York, N.Y., volume 2, p. 335; Higuchi et al., in *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, PA, **1985**, p. 301). Emulsions are often biphasic systems comprising of two immiscible liquid phases intimately mixed and dispersed with each other. In general, emulsions may be either water-in-oil (w/o) or of the oil-in-water (o/w) variety. When an aqueous phase is finely divided into and dispersed as minute droplets into a bulk oily phase the resulting composition is called a water-in-oil (w/o) emulsion. Alternatively, when an oily phase is finely divided into and dispersed as minute droplets into a bulk aqueous phase the resulting composition is called an oil-in-water (o/w) emulsion. Emulsions may contain additional components in addition to the dispersed phases and the active drug which may be present as a solution in either the aqueous phase, oily phase or itself as a separate phase. Pharmaceutical excipients such as emulsifiers, stabilizers, dyes, and anti-oxidants may also be present in emulsions as needed. Pharmaceutical emulsions may also be multiple emulsions that are comprised of more than two phases such as, for example, in the case of oil-in-water-in-oil (o/w/o) and water-in-oil-in-water (w/o/w) emulsions. Such complex formulations often provide certain advantages that simple binary emulsions do not. Multiple emulsions in which individual oil droplets of an o/w emulsion enclose small water droplets constitute a w/o/w emulsion. Likewise a system of oil droplets enclosed in globules of water stabilized in an oily continuous provides an o/w/o emulsion.

-31-

Emulsions are characterized by little or no thermodynamic stability. Often, the dispersed or discontinuous phase of the emulsion is well dispersed into the external or continuous phase and maintained in this form through the means of emulsifiers or the viscosity of the formulation. Either of the phases of the emulsion may be a semisolid or a solid, as is the case of emulsion-style ointment bases and creams. Other means of stabilizing emulsions entail the use of emulsifiers that may be incorporated into either phase of the emulsion. Emulsifiers may broadly be classified into four categories: synthetic surfactants, naturally occurring emulsifiers, absorption bases, and finely dispersed solids (Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).

Synthetic surfactants, also known as surface active agents, have found wide applicability in the formulation of emulsions and have been reviewed in the literature (Rieger, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), Marcel Dekker, Inc., New York, N.Y., 1988, volume 1, p. 199). Surfactants are typically amphiphilic and comprise a hydrophilic and a hydrophobic portion. The ratio of the hydrophilic to the hydrophobic nature of the surfactant has been termed the hydrophile/lipophile balance (HLB) and is a valuable tool in categorizing and selecting surfactants in the preparation of formulations. Surfactants may be classified into different classes based on the nature of the hydrophilic group: nonionic, anionic, cationic and amphoteric (Rieger, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285).

Naturally occurring emulsifiers used in emulsion formulations include lanolin, beeswax, phosphatides, lecithin and acacia. Absorption bases possess hydrophilic properties such that they can soak up water to form w/o emulsions yet retain their semisolid consistencies, such as anhydrous lanolin and hydrophilic petrolatum. Finely divided solids have also

-32-

been used as good emulsifiers especially in combination with surfactants and in viscous preparations. These include polar inorganic solids, such as heavy metal hydroxides, nonswelling clays such as bentonite, attapulgite, hectorite, kaolin, montmorillonite, colloidal aluminum silicate and colloidal magnesium aluminum silicate, pigments and nonpolar solids such as carbon or glyceryl tristearate.

A large variety of non-emulsifying materials are also included in emulsion formulations and contribute to the properties of emulsions. These include fats, oils, waxes, fatty acids, fatty alcohols, fatty esters, humectants, hydrophilic colloids, preservatives and antioxidants (Block, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 335; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).

Hydrophilic colloids or hydrocolloids include naturally occurring gums and synthetic polymers such as polysaccharides (for example, acacia, agar, alginic acid, carrageenan, guar gum, karaya gum, and tragacanth), cellulose derivatives (for example, carboxymethylcellulose and carboxypropylcellulose), and synthetic polymers (for example, carbomers, cellulose ethers, and carboxyvinyl polymers). These disperse or swell in water to form colloidal solutions that stabilize emulsions by forming strong interfacial films around the dispersed-phase droplets and by increasing the viscosity of the external phase.

Since emulsions often contain a number of ingredients such as carbohydrates, proteins, sterols and phosphatides that may readily support the growth of microbes, these formulations often incorporate preservatives. Commonly used preservatives included in emulsion formulations include methyl paraben, propyl paraben, quaternary ammonium salts, benzalkonium chloride, esters of p-hydroxybenzoic acid, and boric acid. Antioxidants are also commonly added to emulsion formulations to prevent deterioration of the formulation. Antioxidants used may be free radical scavengers such as tocopherols, alkyl gallates, butylated hydroxyanisole, butylated hydroxytoluene, or reducing agents

-33-

such as ascorbic acid and sodium metabisulfite, and antioxidant synergists such as citric acid, tartaric acid, and lecithin.

The application of emulsion formulations via dermatological, oral and parenteral routes and methods for their manufacture have been reviewed in the literature (Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), **1988**, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). Emulsion formulations for oral delivery have been very widely used because of reasons of ease of formulation, efficacy from an absorption and bioavailability standpoint. (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), **1988**, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), **1988**, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). Mineral-oil base laxatives, oil-soluble vitamins and high fat nutritive preparations are among the materials that have commonly been administered orally as o/w emulsions.

In one embodiment of the present invention, the compositions of oligonucleotides and nucleic acids are formulated as microemulsions. A microemulsion may be defined as a system of water, oil and amphiphile which is a single optically isotropic and thermodynamically stable liquid solution (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), **1988**, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245). Typically microemulsions are systems that are prepared by first dispersing an oil in an aqueous surfactant solution and then adding a sufficient amount of a fourth component, generally an intermediate chain-length alcohol to form a transparent system. Therefore, microemulsions have also been described as thermodynamically stable, isotropically clear dispersions of two immiscible liquids that are stabilized by interfacial films of surface-active molecules (Leung and Shah, *in: Controlled Release of Drugs: Polymers and Aggregate Systems*, Rosoff, M., Ed., **1989**, VCH Publishers, New York, pages 185-215). Microemulsions commonly are prepared via a combination of three to five components that include oil, water, surfactant, cosurfactant and electrolyte. Whether the microemulsion is of

-34-

the water-in-oil (w/o) or an oil-in-water (o/w) type is dependent on the properties of the oil and surfactant used and on the structure and geometric packing of the polar heads and hydrocarbon tails of the surfactant molecules (Schott, in  
5 *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, PA, **1985**, p. 271).

The phenomenological approach utilizing phase diagrams has been extensively studied and has yielded a comprehensive knowledge, to one skilled in the art, of how to formulate  
10 microemulsions (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), **1988**, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245; Block, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), **1988**, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 335). Compared to  
15 conventional emulsions, microemulsions offer the advantage of solubilizing water-insoluble drugs in a formulation of thermodynamically stable droplets that are formed spontaneously.

Surfactants used in the preparation of microemulsions include, but are not limited to, ionic surfactants, non-ionic  
20 surfactants, Brij 96, polyoxyethylene oleyl ethers, polyglycerol fatty acid esters, tetraglycerol monolaurate (ML310), tetraglycerol monooleate (MO310), hexaglycerol monooleate (PO310), hexaglycerol pentaoleate (PO500), decaglycerol monocaprate (MCA750), decaglycerol monooleate (MO750),  
25 decaglycerol sequioleate (SO750), decaglycerol decaoleate (DAO750), alone or in combination with cosurfactants. The cosurfactant, usually a short-chain alcohol such as ethanol, 1-propanol, and 1-butanol, serves to increase the interfacial fluidity by penetrating into the surfactant film and  
30 consequently creating a disordered film because of the void space generated among surfactant molecules. Microemulsions may, however, be prepared without the use of cosurfactants and alcohol-free self-emulsifying microemulsion systems are known in the art. The aqueous phase may typically be, but is not limited  
35 to, water, an aqueous solution of the drug, glycerol, PEG300, PEG400, polyglycerols, propylene glycols, and derivatives of ethylene glycol. The oil phase may include, but is not limited to, materials such as Captex 300, Captex 355, Capmul MCM, fatty

-35-

acid esters, medium chain (C8-C12) mono, di, and tri-glycerides, polyoxyethylated glyceryl fatty acid esters, fatty alcohols, polyglycolized glycerides, saturated polyglycolized C8-C10 glycerides, vegetable oils and silicone oil.

5        Microemulsions are particularly of interest from the standpoint of drug solubilization and the enhanced absorption of drugs. Lipid based microemulsions (both o/w and w/o) have been proposed to enhance the oral bioavailability of drugs, including peptides (Constantinides et al., *Pharmaceutical Research*, **1994**,  
10    11, 1385-1390; Ritschel, *Meth. Find. Exp. Clin. Pharmacol.*, **1993**, 13, 205). Microemulsions afford advantages of improved drug solubilization, protection of drug from enzymatic hydrolysis, possible enhancement of drug absorption due to surfactant-induced alterations in membrane fluidity and  
15    permeability, ease of preparation, ease of oral administration over solid dosage forms, improved clinical potency, and decreased toxicity (Constantinides et al., *Pharmaceutical Research*, **1994**, 11, 1385; Ho et al., *J. Pharm. Sci.*, **1996**, 85, 138-143). Often microemulsions may form spontaneously when  
20    their components are brought together at ambient temperature. This may be particularly advantageous when formulating thermolabile drugs, peptides or oligonucleotides. Microemulsions have also been effective in the transdermal delivery of active components in both cosmetic and  
25    pharmaceutical applications. It is expected that the microemulsion compositions and formulations of the present invention will facilitate the increased systemic absorption of oligonucleotides and nucleic acids from the gastrointestinal tract, as well as improve the local cellular uptake of  
30    oligonucleotides and nucleic acids within the gastrointestinal tract, vagina, buccal cavity and other areas of administration.

Microemulsions of the present invention may also contain additional components and additives such as sorbitan monostearate (Grill 3), Labrasol, and penetration enhancers to  
35    improve the properties of the formulation and to enhance the absorption of the oligonucleotides and nucleic acids of the present invention. Penetration enhancers used in the microemulsions of the present invention may be classified as

-36-

belonging to one of five broad categories - surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants (Lee *et al.*, *Critical Reviews in Therapeutic Drug Carrier Systems*, **1991**, p. 92). Each of these classes has been  
5 discussed above.

### Liposomes

There are many organized surfactant structures besides microemulsions that have been studied and used for the  
10 formulation of drugs. These include monolayers, micelles, bilayers and vesicles. Vesicles, such as liposomes, have attracted great interest because of their specificity and the duration of action they offer from the standpoint of drug delivery. As used in the present invention, the term "liposome"  
15 means a vesicle composed of amphiphilic lipids arranged in a spherical bilayer or bilayers.

Liposomes are unilamellar or multilamellar vesicles which have a membrane formed from a lipophilic material and an aqueous interior. The aqueous portion contains the composition to be  
20 delivered. Cationic liposomes possess the advantage of being able to fuse to the cell wall. Non-cationic liposomes, although not able to fuse as efficiently with the cell wall, are taken up by macrophages *in vivo*.

In order to cross intact mammalian skin, lipid vesicles  
25 must pass through a series of fine pores, each with a diameter less than 50 nm, under the influence of a suitable transdermal gradient. Therefore, it is desirable to use a liposome which is highly deformable and able to pass through such fine pores.

Further advantages of liposomes include; liposomes obtained  
30 from natural phospholipids are biocompatible and biodegradable; liposomes can incorporate a wide range of water and lipid soluble drugs; liposomes can protect encapsulated drugs in their internal compartments from metabolism and degradation (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker  
35 (Eds.), **1988**, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245). Important considerations in the preparation of liposome formulations are the lipid surface charge, vesicle size and the aqueous volume of the liposomes.

-37-

Liposomes are useful for the transfer and delivery of active ingredients to the site of action. Because the liposomal membrane is structurally similar to biological membranes, when liposomes are applied to a tissue, the liposomes start to merge with the cellular membranes. As the merging of the liposome and cell progresses, the liposomal contents are emptied into the cell where the active agent may act.

Liposomal formulations have been the focus of extensive investigation as the mode of delivery for many drugs. There is growing evidence that for topical administration, liposomes present several advantages over other formulations. Such advantages include reduced side-effects related to high systemic absorption of the administered drug, increased accumulation of the administered drug at the desired target, and the ability to administer a wide variety of drugs, both hydrophilic and hydrophobic, into the skin.

Several reports have detailed the ability of liposomes to deliver agents including high-molecular weight DNA into the skin. Compounds including analgesics, antibodies, hormones and high-molecular weight DNAs have been administered to the skin. The majority of applications resulted in the targeting of the upper epidermis.

Liposomes fall into two broad classes. Cationic liposomes are positively charged liposomes which interact with the negatively charged DNA molecules to form a stable complex. The positively charged DNA/liposome complex binds to the negatively charged cell surface and is internalized in an endosome. Due to the acidic pH within the endosome, the liposomes are ruptured, releasing their contents into the cell cytoplasm (Wang *et al.*, *Biochem. Biophys. Res. Commun.*, **1987**, 147, 980-985).

Liposomes which are pH-sensitive or negatively-charged, entrap DNA rather than complex with it. Since both the DNA and the lipid are similarly charged, repulsion rather than complex formation occurs. Nevertheless, some DNA is entrapped within the aqueous interior of these liposomes. pH-sensitive liposomes have been used to deliver DNA encoding the thymidine kinase gene to cell monolayers in culture. Expression of the exogenous gene was

-38-

detected in the target cells (Zhou et al., *Journal of Controlled Release*, **1992**, 19, 269-274).

One major type of liposomal composition includes phospholipids other than naturally-derived phosphatidylcholine.

5 Neutral liposome compositions, for example, can be formed from dimyristoyl phosphatidylcholine (DMPC) or dipalmitoyl phosphatidylcholine (DPPC). Anionic liposome compositions generally are formed from dimyristoyl phosphatidylglycerol, while anionic fusogenic liposomes are formed primarily from  
10 dioleoyl phosphatidylethanolamine (DOPE). Another type of liposomal composition is formed from phosphatidylcholine (PC) such as, for example, soybean PC, and egg PC. Another type is formed from mixtures of phospholipid and/or phosphatidylcholine and/or cholesterol.

15 Several studies have assessed the topical delivery of liposomal drug formulations to the skin. Application of liposomes containing interferon to guinea pig skin resulted in a reduction of skin herpes sores while delivery of interferon via other means (e.g. as a solution or as an emulsion) were  
20 ineffective (Weiner et al., *Journal of Drug Targeting*, **1992**, 2, 405-410). Further, an additional study tested the efficacy of interferon administered as part of a liposomal formulation to the administration of interferon using an aqueous system, and concluded that the liposomal formulation was superior to aqueous  
25 administration (du Plessis et al., *Antiviral Research*, **1992**, 18, 259-265).

Non-ionic liposomal systems have also been examined to determine their utility in the delivery of drugs to the skin, in particular systems comprising non-ionic surfactant and  
30 cholesterol. Non-ionic liposomal formulations comprising Novasome™ I (glyceryl dilaurate/cholesterol/polyoxyethylene-10-stearyl ether) and Novasome™ II (glyceryl distearate/cholesterol/polyoxyethylene-10-stearyl ether) were used to deliver cyclosporin-A into the dermis of mouse skin. Results  
35 indicated that such non-ionic liposomal systems were effective in facilitating the deposition of cyclosporin-A into different layers of the skin (Hu et al. *S.T.P. Pharma. Sci.*, **1994**, 4, 6, 466).

-39-

Liposomes also include "sterically stabilized" liposomes, a term which, as used herein, refers to liposomes comprising one or more specialized lipids that, when incorporated into liposomes, result in enhanced circulation lifetimes relative to liposomes lacking such specialized lipids. Examples of sterically stabilized liposomes are those in which part of the vesicle-forming lipid portion of the liposome (A) comprises one or more glycolipids, such as monosialoganglioside G<sub>M1</sub>, or (B) is derivatized with one or more hydrophilic polymers, such as a polyethylene glycol (PEG) moiety. While not wishing to be bound by any particular theory, it is thought in the art that, at least for sterically stabilized liposomes containing gangliosides, sphingomyelin, or PEG-derivatized lipids, the enhanced circulation half-life of these sterically stabilized liposomes derives from a reduced uptake into cells of the reticuloendothelial system (RES) (Allen et al., *FEBS Letters*, **1987**, 223, 42; Wu et al., *Cancer Research*, **1993**, 53, 3765).

Various liposomes comprising one or more glycolipids are known in the art. Papahadjopoulos et al. (*Ann. N.Y. Acad. Sci.*, **1987**, 507, 64) reported the ability of monosialoganglioside G<sub>M1</sub>, galactocerebroside sulfate and phosphatidylinositol to improve blood half-lives of liposomes. These findings were expounded upon by Gabizon et al. (*Proc. Natl. Acad. Sci. U.S.A.*, **1988**, 85, 6949). U.S. Patent No. 4,837,028 and WO 88/04924, both to Allen et al., disclose liposomes comprising (1) sphingomyelin and (2) the ganglioside G<sub>M1</sub> or a galactocerebroside sulfate ester. U.S. Patent No. 5,543,152 (Webb et al.) discloses liposomes comprising sphingomyelin. Liposomes comprising 1,2-sn-dimyristoylphosphatidylcholine are disclosed in WO 97/13499 (Lim et al.).

Many liposomes comprising lipids derivatized with one or more hydrophilic polymers, and methods of preparation thereof, are known in the art. Sunamoto et al. (*Bull. Chem. Soc. Jpn.*, **1980**, 53, 2778) described liposomes comprising a nonionic detergent, 2C<sub>12</sub>15G, that contains a PEG moiety. Illum et al. (*FEBS Lett.*, **1984**, 167, 79) noted that hydrophilic coating of polystyrene particles with polymeric glycols results in significantly enhanced blood half-lives. Synthetic

-40-

phospholipids modified by the attachment of carboxylic groups of polyalkylene glycols (e.g., PEG) are described by Sears (U.S. Patent Nos. 4,426,330 and 4,534,899). Klibanov et al. (*FEBS Lett.*, **1990**, 268, 235) described experiments demonstrating that liposomes comprising phosphatidylethanolamine (PE) derivatized with PEG or PEG stearate have significant increases in blood circulation half-lives. Blume et al. (*Biochimica et Biophysica Acta*, **1990**, 1029, 91) extended such observations to other PEG-derivatized phospholipids, e.g., DSPE-PEG, formed from the combination of distearoylphosphatidylethanolamine (DSPE) and PEG. Liposomes having covalently bound PEG moieties on their external surface are described in European Patent No. EP 0 445 131 B1 and WO 90/04384 to Fisher. Liposome compositions containing 1-20 mole percent of PE derivatized with PEG, and methods of use thereof, are described by Woodle et al. (U.S. Patent Nos. 5,013,556 and 5,356,633) and Martin et al. (U.S. Patent No. 5,213,804 and European Patent No. EP 0 496 813 B1). Liposomes comprising a number of other lipid-polymer conjugates are disclosed in WO 91/05545 and U.S. Patent No. 5,225,212 (both to Martin et al.) and in WO 94/20073 (Zalipsky et al.) Liposomes comprising PEG-modified ceramide lipids are described in WO 96/10391 (Choi et al.). U.S. Patent Nos. 5,540,935 (Miyazaki et al.) and 5,556,948 (Tagawa et al.) describe PEG-containing liposomes that can be further derivatized with functional moieties on their surfaces.

A limited number of liposomes comprising nucleic acids are known in the art. WO 96/40062 to Thierry et al. discloses methods for encapsulating high molecular weight nucleic acids in liposomes. U.S. Patent No. 5,264,221 to Tagawa et al. discloses protein-bonded liposomes and asserts that the contents of such liposomes may include an antisense RNA. U.S. Patent No. 5,665,710 to Rahman et al. describes certain methods of encapsulating oligodeoxynucleotides in liposomes. WO 97/04787 to Love et al. discloses liposomes comprising antisense oligonucleotides targeted to the raf gene.

Transfersomes are yet another type of liposomes, and are highly deformable lipid aggregates which are attractive candidates for drug delivery vehicles. Transfersomes may be

-41-

described as lipid droplets which are so highly deformable that they are easily able to penetrate through pores which are smaller than the droplet. Transfersomes are adaptable to the environment in which they are used, e.g. they are self-

5 optimizing (adaptive to the shape of pores in the skin), self-repairing, frequently reach their targets without fragmenting, and often self-loading. To make transfersomes it is possible to add surface edge-activators, usually surfactants, to a standard liposomal composition. Transfersomes have been used to deliver  
10 serum albumin to the skin. The transfersome-mediated delivery of serum albumin has been shown to be as effective as subcutaneous injection of a solution containing serum albumin.

Surfactants find wide application in formulations such as emulsions (including microemulsions) and liposomes. The most  
15 common way of classifying and ranking the properties of the many different types of surfactants, both natural and synthetic, is by the use of the hydrophile/lipophile balance (HLB). The nature of the hydrophilic group (also known as the "head") provides the most useful means for categorizing the different  
20 surfactants used in formulations (Rieger, in *Pharmaceutical Dosage Forms*, Marcel Dekker, Inc., New York, NY, 1988, p. 285).

If the surfactant molecule is not ionized, it is classified as a nonionic surfactant. Nonionic surfactants find wide application in pharmaceutical and cosmetic products and are  
25 usable over a wide range of pH values. In general their HLB values range from 2 to about 18 depending on their structure. Nonionic surfactants include nonionic esters such as ethylene glycol esters, propylene glycol esters, glyceryl esters, polyglyceryl esters, sorbitan esters, sucrose esters, and  
30 ethoxylated esters. Nonionic alkanolamides and ethers such as fatty alcohol ethoxylates, propoxylated alcohols, and ethoxylated/propoxylated block polymers are also included in this class. The polyoxyethylene surfactants are the most popular members of the nonionic surfactant class.

35 If the surfactant molecule carries a negative charge when it is dissolved or dispersed in water, the surfactant is classified as anionic. Anionic surfactants include carboxylates such as soaps, acyl lactylates, acyl amides of amino acids,

-42-

esters of sulfuric acid such as alkyl sulfates and ethoxylated alkyl sulfates, sulfonates such as alkyl benzene sulfonates, acyl isethionates, acyl taurates and sulfosuccinates, and phosphates. The most important members of the anionic surfactant class are the alkyl sulfates and the soaps.

If the surfactant molecule carries a positive charge when it is dissolved or dispersed in water, the surfactant is classified as cationic. Cationic surfactants include quaternary ammonium salts and ethoxylated amines. The quaternary ammonium salts are the most used members of this class.

If the surfactant molecule has the ability to carry either a positive or negative charge, the surfactant is classified as amphoteric. Amphoteric surfactants include acrylic acid derivatives, substituted alkylamides, N-alkylbetaines and phosphatides.

The use of surfactants in drug products, formulations and in emulsions has been reviewed (Rieger, in *Pharmaceutical Dosage Forms*, Marcel Dekker, Inc., New York, NY, 1988, p. 285).

## Penetration Enhancers

In one embodiment, the present invention employs various penetration enhancers to effect the efficient delivery of nucleic acids, particularly oligonucleotides, to the skin of animals. Most drugs are present in solution in both ionized and nonionized forms. However, usually only lipid soluble or lipophilic drugs readily cross cell membranes. It has been discovered that even non-lipophilic drugs may cross cell membranes if the membrane to be crossed is treated with a penetration enhancer. In addition to aiding the diffusion of non-lipophilic drugs across cell membranes, penetration enhancers also enhance the permeability of lipophilic drugs.

Penetration enhancers may be classified as belonging to one of five broad categories, i.e., surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p.92). Each of the above mentioned classes of penetration enhancers are described below in greater detail.

-43-

Surfactants: In connection with the present invention, surfactants (or "surface-active agents") are chemical entities which, when dissolved in an aqueous solution, reduce the surface tension of the solution or the interfacial tension between the aqueous solution and another liquid, with the result that absorption of oligonucleotides through the mucosa is enhanced. In addition to bile salts and fatty acids, these penetration enhancers include, for example, sodium lauryl sulfate, polyoxyethylene-9-lauryl ether and polyoxyethylene-20-cetyl ether) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, **1991**, p.92); and perfluorochemical emulsions, such as FC-43. Takahashi et al., *J. Pharm. Pharmacol.*, **1988**, 40, 252).

Fatty acids: Various fatty acids and their derivatives which act as penetration enhancers include, for example, oleic acid, lauric acid, capric acid (n-decanoic acid), myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, monoolein (1-monooleoyl-rac-glycerol), dilaurin, caprylic acid, arachidonic acid, glycerol 1-monocaprate, 1-dodecylazacycloheptan-2-one, acylcarnitines, acylcholines, C<sub>1-10</sub> alkyl esters thereof (e.g., methyl, isopropyl and t-butyl), and mono- and di-glycerides thereof (i.e., oleate, laurate, caprate, myristate, palmitate, stearate, linoleate, etc.) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, **1991**, p.92; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, **1990**, 7, 1-33; El Hariri et al., *J. Pharm. Pharmacol.*, **1992**, 44, 651-654).

Bile salts: The physiological role of bile includes the facilitation of dispersion and absorption of lipids and fat-soluble vitamins (Brunton, Chapter 38 in: Goodman & Gilman's *The Pharmacological Basis of Therapeutics*, 9th Ed., Hardman et al. Eds., McGraw-Hill, New York, **1996**, pp. 934-935). Various natural bile salts, and their synthetic derivatives, act as penetration enhancers. Thus the term "bile salts" includes any of the naturally occurring components of bile as well as any of their synthetic derivatives. The bile salts of the invention include, for example, cholic acid (or its pharmaceutically acceptable sodium salt, sodium cholate), dehydrocholic acid

-44-

(sodium dehydrocholate), deoxycholic acid (sodium deoxycholate), glucolic acid (sodium glucolate), glycholic acid (sodium glycocholate), glycodeoxycholic acid (sodium glycodeoxycholate), taurocholic acid (sodium taurocholate), taurodeoxycholic acid (sodium taurodeoxycholate), chenodeoxycholic acid (sodium chenodeoxycholate), ursodeoxycholic acid (UDCA), sodium tauro-24,25-dihydro-fusidate (STDHF), sodium glycodihydrofusidate and polyoxyethylene-9-lauryl ether (POE) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, **1991**, page 92; Swinyard, Chapter 39 In: *Remington's Pharmaceutical Sciences*, 18th Ed., Gennaro, ed., Mack Publishing Co., Easton, PA, **1990**, pages 782-783; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, **1990**, 7, 1-33; Yamamoto et al., *J. Pharm. Exp. Ther.*, **1992**, 263, 25; Yamashita et al., *J. Pharm. Sci.*, **1990**, 79, 579-583).

Chelating Agents: Chelating agents, as used in connection with the present invention, can be defined as compounds that remove metallic ions from solution by forming complexes therewith, with the result that absorption of oligonucleotides through the mucosa is enhanced. With regards to their use as penetration enhancers in the present invention, chelating agents have the added advantage of also serving as DNase inhibitors, as most characterized DNA nucleases require a divalent metal ion for catalysis and are thus inhibited by chelating agents (Jarrett, *J. Chromatogr.*, **1993**, 618, 315-339). Chelating agents of the invention include but are not limited to disodium ethylenediaminetetraacetate (EDTA), citric acid, salicylates (e.g., sodium salicylate, 5-methoxysalicylate and homovanilate), *N*-acyl derivatives of collagen, laureth-9 and *N*-amino acyl derivatives of beta-diketones (enamines) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, **1991**, page 92; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, **1990**, 7, 1-33; Buur et al., *J. Control Rel.*, **1990**, 14, 43-51).

Non-chelating non-surfactants: As used herein, non-chelating non-surfactant penetration enhancing compounds can be defined as compounds that demonstrate insignificant activity as

-45-

chelating agents or as surfactants but that nonetheless enhance absorption of oligonucleotides through the alimentary mucosa (Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, **1990**, 7, 1-33). This class of penetration enhancers include, for example, unsaturated cyclic ureas, 1-alkyl- and 1-alkenylazacyclo-alkanone derivatives (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, **1991**, page 92); and non-steroidal anti-inflammatory agents such as diclofenac sodium, indomethacin and phenylbutazone (Yamashita et al., *J. Pharm. Pharmacol.*, **1987**, 39, 621-626).

Agents that enhance uptake of oligonucleotides at the cellular level may also be added to the pharmaceutical and other compositions of the present invention. For example, cationic lipids, such as lipofectin (Junichi et al, U.S. Patent No. 5,705,188), cationic glycerol derivatives, and polycationic molecules, such as polylysine (Lollo et al., PCT Application WO 97/30731), are also known to enhance the cellular uptake of oligonucleotides.

Other agents may be utilized to enhance the penetration of the administered nucleic acids, including glycols such as ethylene glycol and propylene glycol, pyrrols such as 2-pyrrol, azones, and terpenes such as limonene and menthone.

#### Carriers

Certain compositions of the present invention also incorporate carrier compounds in the formulation. As used herein, "carrier compound" or "carrier" can refer to a nucleic acid, or analog thereof, which is inert (*i.e.*, does not possess biological activity *per se*) but is recognized as a nucleic acid by *in vivo* processes that reduce the bioavailability of a nucleic acid having biological activity by, for example, degrading the biologically active nucleic acid or promoting its removal from circulation. The coadministration of a nucleic acid and a carrier compound, typically with an excess of the latter substance, can result in a substantial reduction of the amount of nucleic acid recovered in the liver, kidney or other extracirculatory reservoirs, presumably due to competition between the carrier compound and the nucleic acid for a common

-46-

receptor. For example, the recovery of a partially phosphorothioate oligonucleotide in hepatic tissue can be reduced when it is coadministered with polyinosinic acid, dextran sulfate, polycytidic acid or 4-acetamido-4'-isothiocyanostilbene-2,2'-disulfonic acid (Miyao *et al.*, *Antisense Res. Dev.*, **1995**, 5, 115-121; Takakura *et al.*, *Antisense & Nucl. Acid Drug Dev.*, **1996**, 6, 177-183).

#### Excipients

In contrast to a carrier compound, a "pharmaceutical carrier" or "excipient" is a pharmaceutically acceptable solvent, suspending agent or any other pharmacologically inert vehicle for delivering one or more nucleic acids to an animal. The excipient may be liquid or solid and is selected, with the planned manner of administration in mind, so as to provide for the desired bulk, consistency, etc., when combined with a nucleic acid and the other components of a given pharmaceutical composition. Typical pharmaceutical carriers include, but are not limited to, binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose, etc.); fillers (e.g., lactose and other sugars, microcrystalline cellulose, pectin, gelatin, calcium sulfate, ethyl cellulose, polyacrylates or calcium hydrogen phosphate, etc.); lubricants (e.g., magnesium stearate, talc, silica, colloidal silicon dioxide, stearic acid, metallic stearates, hydrogenated vegetable oils, corn starch, polyethylene glycols, sodium benzoate, sodium acetate, etc.); disintegrants (e.g., starch, sodium starch glycolate, etc.); and wetting agents (e.g., sodium lauryl sulphate, etc.).

Pharmaceutically acceptable organic or inorganic excipient suitable for non-parenteral administration which do not deleteriously react with nucleic acids can also be used to formulate the compositions of the present invention. Suitable pharmaceutically acceptable carriers include, but are not limited to, water, salt solutions, alcohols, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.

-47-

Formulations for topical administration of nucleic acids may include sterile and non-sterile aqueous solutions, non-aqueous solutions in common solvents such as alcohols, or solutions of the nucleic acids in liquid or solid oil bases.

5 The solutions may also contain buffers, diluents and other suitable additives. Pharmaceutically acceptable organic or inorganic excipients suitable for non-parenteral administration which do not deleteriously react with nucleic acids can be used.

Suitable pharmaceutically acceptable excipients include,  
10 but are not limited to, water, salt solutions, alcohol, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.

#### 15 Other Components

The compositions of the present invention may additionally contain other adjunct components conventionally found in pharmaceutical compositions, at their art-established usage levels. Thus, for example, the compositions may contain  
20 additional, compatible, pharmaceutically-active materials such as, for example, antipruritics, astringents, local anesthetics or anti-inflammatory agents, or may contain additional materials useful in physically formulating various dosage forms of the compositions of the present invention, such as dyes, flavoring  
25 agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers. However, such materials, when added, should not unduly interfere with the biological activities of the components of the compositions of the present invention. The formulations can be sterilized and, if desired, mixed with  
30 auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings and/or aromatic substances and the like which do not deleteriously interact with the nucleic acid(s) of the formulation.

35 Aqueous suspensions may contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

-48-

Certain embodiments of the invention provide pharmaceutical compositions containing (a) one or more antisense compounds and (b) one or more other chemotherapeutic agents which function by a non-antisense mechanism. Examples of such chemotherapeutic agents include but are not limited to daunorubicin, daunomycin, dactinomycin, doxorubicin, epirubicin, idarubicin, esorubicin, bleomycin, mafosfamide, ifosfamide, cytosine arabinoside, bis-chloroethylnitrosurea, busulfan, mitomycin C, actinomycin D, mithramycin, prednisone, hydroxyprogesterone, testosterone, tamoxifen, dacarbazine, procarbazine, hexamethylmelamine, pentamethylmelamine, mitoxantrone, amsacrine, chlorambucil, methylcyclohexylnitrosurea, nitrogen mustards, melphalan, cyclophosphamide, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-azacytidine, hydroxyurea, deoxycoformycin, 4-hydroxyperoxycyclophosphoramide, 5-fluorouracil (5-FU), 5-fluorodeoxyuridine (5-FUdR), methotrexate (MTX), colchicine, taxol, vincristine, vinblastine, etoposide (VP-16), trimetrexate, irinotecan, topotecan, gemcitabine, teniposide, cisplatin and diethylstilbestrol (DES). See, generally, *The Merck Manual of Diagnosis and Therapy*, 15th Ed. **1987**, pp. 1206-1228, Berkow et al., eds., Rahway, N.J. When used with the compounds of the invention, such chemotherapeutic agents may be used individually (e.g., 5-FU and oligonucleotide), sequentially (e.g., 5-FU and oligonucleotide for a period of time followed by MTX and oligonucleotide), or in combination with one or more other such chemotherapeutic agents (e.g., 5-FU, MTX and oligonucleotide, or 5-FU, radiotherapy and oligonucleotide). Anti-inflammatory drugs, including but not limited to nonsteroidal anti-inflammatory drugs and corticosteroids, and antiviral drugs, including but not limited to ribivirin, vidarabine, acyclovir and ganciclovir, may also be combined in compositions of the invention. See, generally, *The Merck Manual of Diagnosis and Therapy*, 15th Ed., Berkow et al., eds., **1987**, Rahway, N.J., pages 2499-2506 and 46-49, respectively). Other non-antisense chemotherapeutic agents are also within the scope of this invention. Two or more combined compounds may be used together or sequentially.

In another related embodiment, compositions of the

-49-

invention may contain one or more antisense compounds, particularly oligonucleotides, targeted to a first nucleic acid and one or more additional antisense compounds targeted to a second nucleic acid target. Numerous examples of antisense  
5 compounds are known in the art. Two or more combined compounds may be used together or sequentially.

The formulation of therapeutic compositions and their subsequent administration is believed to be within the skill of those in the art. Dosing is dependent on severity and  
10 responsiveness of the disease state to be treated, with the course of treatment lasting from several days to several months, or until a cure is effected or a diminution of the disease state is achieved. Optimal dosing schedules can be calculated from measurements of drug accumulation in the body of the patient.  
15 Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates. Optimum dosages may vary depending on the relative potency of individual oligonucleotides, and can generally be estimated based on  $EC_{50}$ s found to be effective in in vitro and in vivo animal models. In  
20 general, dosage is from 0.01 ug to 100 g per kg of body weight, and may be given once or more daily, weekly, monthly or yearly, or even once every 2 to 20 years. Persons of ordinary skill in the art can easily estimate repetition rates for dosing based on measured residence times and concentrations of the drug in  
25 bodily fluids or tissues. Following successful treatment, it may be desirable to have the patient undergo maintenance therapy to prevent the recurrence of the disease state, wherein the oligonucleotide is administered in maintenance doses, ranging from 0.01 ug to 100 g per kg of body weight, once or more daily,  
30 to once every 20 years.

While the present invention has been described with specificity in accordance with certain of its preferred embodiments, the following examples serve only to illustrate the invention and are not intended to limit the same.

-50-

**EXAMPLES****Example 1****5 Nucleoside Phosphoramidites for Oligonucleotide Synthesis  
Deoxy and 2'-alkoxy amidites**

2'-Deoxy and 2'-methoxy beta-cyanoethyl-diisopropyl phosphoramidites were purchased from commercial sources (e.g. ChemGenes, Needham MA or Glen Research, Inc. Sterling VA).

10 Other 2'-O-alkoxy substituted nucleoside amidites are prepared as described in U.S. Patent 5,506,351, herein incorporated by reference. For oligonucleotides synthesized using 2'-alkoxy amidites, the standard cycle for unmodified oligonucleotides was utilized, except the wait step after pulse delivery of tetrazole  
15 and base was increased to 360 seconds.

Oligonucleotides containing 5-methyl-2'-deoxycytidine (5-Me-C) nucleotides were synthesized according to published methods [Sanghvi, et. al., *Nucleic Acids Research*, **1993**, 21, 3197-3203] using commercially available phosphoramidites (Glen  
20 Research, Sterling VA or ChemGenes, Needham MA).

**2'-Fluoro amidites****2'-Fluorodeoxyadenosine amidites**

2'-fluoro oligonucleotides were synthesized as described  
25 previously [Kawasaki, et. al., *J. Med. Chem.*, **1993**, 36, 831-841] and United States patent 5,670,633, herein incorporated by reference. Briefly, the protected nucleoside N6-benzoyl-2'-deoxy-2'-fluoroadenosine was synthesized utilizing commercially available 9-beta-D-arabinofuranosyladenine as starting material  
30 and by modifying literature procedures whereby the 2'-alpha-fluoro atom is introduced by a S<sub>N</sub>2-displacement of a 2'-beta-trityl group. Thus N6-benzoyl-9-beta-D-arabinofuranosyladenine was selectively protected in moderate yield as the 3',5'-ditetrahydropyranyl (THP) intermediate. Deprotection of the THP  
35 and N6-benzoyl groups was accomplished using standard methodologies and standard methods were used to obtain the 5'-dimethoxytrityl-(DMT) and 5'-DMT-3'-phosphoramidite intermediates.

-51-

**2'-Fluorodeoxyguanosine**

The synthesis of 2'-deoxy-2'-fluoroguanosine was accomplished using tetraisopropylidisiloxanyl (TPDS) protected 9-beta-D-arabinofuranosylguanine as starting material, and conversion to the intermediate diisobutyryl-arabinofuranosylguanosine. Deprotection of the TPDS group was followed by protection of the hydroxyl group with THP to give diisobutyryl di-THP protected arabinofuranosylguanine. Selective O-deacylation and triflation was followed by treatment of the crude product with fluoride, then deprotection of the THP groups. Standard methodologies were used to obtain the 5'-DMT- and 5'-DMT-3'-phosphoramidites.

**2'-Fluorouridine**

Synthesis of 2'-deoxy-2'-fluorouridine was accomplished by the modification of a literature procedure in which 2,2'-anhydro-1-beta-D-arabinofuranosyluracil was treated with 70% hydrogen fluoride-pyridine. Standard procedures were used to obtain the 5'-DMT and 5'-DMT-3'phosphoramidites.

**2'-Fluorodeoxycytidine**

2'-deoxy-2'-fluorocytidine was synthesized via amination of 2'-deoxy-2'-fluorouridine, followed by selective protection to give N4-benzoyl-2'-deoxy-2'-fluorocytidine. Standard procedures were used to obtain the 5'-DMT and 5'-DMT-3'phosphoramidites.

**2'-O-(2-Methoxyethyl) modified amidites**

2'-O-Methoxyethyl-substituted nucleoside amidites are prepared as follows, or alternatively, as per the methods of Martin, P., *Helvetica Chimica Acta*, **1995**, 78, 486-504.

**2,2'-Anhydro[1-(beta-D-arabinofuranosyl)-5-methyluridine]**

5-Methyluridine (ribosylthymine, commercially available through Yamasa, Choshi, Japan) (72.0 g, 0.279 M), diphenylcarbonate (90.0 g, 0.420 M) and sodium bicarbonate (2.0 g, 0.024 M) were added to DMF (300 mL). The mixture was heated to reflux, with stirring, allowing the evolved carbon dioxide gas

-52-

to be released in a controlled manner. After 1 hour, the slightly darkened solution was concentrated under reduced pressure. The resulting syrup was poured into diethylether (2.5 L), with stirring. The product formed a gum. The ether was  
5 decanted and the residue was dissolved in a minimum amount of methanol (ca. 400 mL). The solution was poured into fresh ether (2.5 L) to yield a stiff gum. The ether was decanted and the gum was dried in a vacuum oven (60°C at 1 mm Hg for 24 h) to give a solid that was crushed to a light tan powder (57 g, 85% crude  
10 yield). The NMR spectrum was consistent with the structure, contaminated with phenol as its sodium salt (ca. 5%). The material was used as is for further reactions (or it can be purified further by column chromatography using a gradient of methanol in ethyl acetate (10-25%) to give a white solid, mp  
15 222-4°C).

**2'-O-Methoxyethyl-5-methyluridine**

2,2'-Anhydro-5-methyluridine (195 g, 0.81 M), tris(2-methoxyethyl)borate (231 g, 0.98 M) and 2-methoxyethanol (1.2 L)  
20 were added to a 2 L stainless steel pressure vessel and placed in a pre-heated oil bath at 160°C. After heating for 48 hours at 155-160°C, the vessel was opened and the solution evaporated to dryness and triturated with MeOH (200 mL). The residue was suspended in hot acetone (1 L). The insoluble salts were  
25 filtered, washed with acetone (150 mL) and the filtrate evaporated. The residue (280 g) was dissolved in CH<sub>3</sub>CN (600 mL) and evaporated. A silica gel column (3 kg) was packed in CH<sub>2</sub>Cl<sub>2</sub>/acetone/MeOH (20:5:3) containing 0.5% Et<sub>3</sub>NH. The residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (250 mL) and adsorbed onto silica (150 g)  
30 prior to loading onto the column. The product was eluted with the packing solvent to give 160 g (63%) of product. Additional material was obtained by reworking impure fractions.

**2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine**

35 2'-O-Methoxyethyl-5-methyluridine (160 g, 0.506 M) was co-evaporated with pyridine (250 mL) and the dried residue dissolved in pyridine (1.3 L). A first aliquot of

-53-

dimethoxytrityl chloride (94.3 g, 0.278 M) was added and the mixture stirred at room temperature for one hour. A second aliquot of dimethoxytrityl chloride (94.3 g, 0.278 M) was added and the reaction stirred for an additional one hour. Methanol (170 mL) was then added to stop the reaction. HPLC showed the presence of approximately 70% product. The solvent was evaporated and triturated with CH<sub>3</sub>CN (200 mL). The residue was dissolved in CHCl<sub>3</sub> (1.5 L) and extracted with 2x500 mL of saturated NaHCO<sub>3</sub> and 2x500 mL of saturated NaCl. The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and evaporated. 275 g of residue was obtained. The residue was purified on a 3.5 kg silica gel column, packed and eluted with EtOAc/hexane/acetone (5:5:1) containing 0.5% Et<sub>3</sub>NH. The pure fractions were evaporated to give 164 g of product. Approximately 20 g additional was obtained from the impure fractions to give a total yield of 183 g (57%).

**3'-O-Acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine**

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine (106 g, 0.167 M), DMF/pyridine (750 mL of a 3:1 mixture prepared from 562 mL of DMF and 188 mL of pyridine) and acetic anhydride (24.38 mL, 0.258 M) were combined and stirred at room temperature for 24 hours. The reaction was monitored by TLC by first quenching the TLC sample with the addition of MeOH. Upon completion of the reaction, as judged by TLC, MeOH (50 mL) was added and the mixture evaporated at 35°C. The residue was dissolved in CHCl<sub>3</sub> (800 mL) and extracted with 2x200 mL of saturated sodium bicarbonate and 2x200 mL of saturated NaCl. The water layers were back extracted with 200 mL of CHCl<sub>3</sub>. The combined organics were dried with sodium sulfate and evaporated to give 122 g of residue (approx. 90% product). The residue was purified on a 3.5 kg silica gel column and eluted using EtOAc/hexane(4:1). Pure product fractions were evaporated to yield 96 g (84%). An additional 1.5 g was recovered from later fractions.

-54-

**3'-O-Acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyl-4-triazoleuridine**

A first solution was prepared by dissolving 3'-O-acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine (96 g, 0.144 M) in CH<sub>3</sub>CN (700 mL) and set aside. Triethylamine (189 mL, 1.44 M) was added to a solution of triazole (90 g, 1.3 M) in CH<sub>3</sub>CN (1 L), cooled to -5°C and stirred for 0.5 h using an overhead stirrer. POCl<sub>3</sub> was added dropwise, over a 30 minute period, to the stirred solution maintained at 0-10°C, and the resulting mixture stirred for an additional 2 hours. The first solution was added dropwise, over a 45 minute period, to the latter solution. The resulting reaction mixture was stored overnight in a cold room. Salts were filtered from the reaction mixture and the solution was evaporated. The residue was dissolved in EtOAc (1 L) and the insoluble solids were removed by filtration. The filtrate was washed with 1x300 mL of NaHCO<sub>3</sub> and 2x300 mL of saturated NaCl, dried over sodium sulfate and evaporated. The residue was triturated with EtOAc to give the title compound.

**2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine**

A solution of 3'-O-acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyl-4-triazoleuridine (103 g, 0.141 M) in dioxane (500 mL) and NH<sub>4</sub>OH (30 mL) was stirred at room temperature for 2 hours. The dioxane solution was evaporated and the residue azeotroped with MeOH (2x200 mL). The residue was dissolved in MeOH (300 mL) and transferred to a 2 liter stainless steel pressure vessel. MeOH (400 mL) saturated with NH<sub>3</sub> gas was added and the vessel heated to 100°C for 2 hours (TLC showed complete conversion). The vessel contents were evaporated to dryness and the residue was dissolved in EtOAc (500 mL) and washed once with saturated NaCl (200 mL). The organics were dried over sodium sulfate and the solvent was evaporated to give 85 g (95%) of the title compound.

**N4-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine**

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine (85

-55-

g, 0.134 M) was dissolved in DMF (800 mL) and benzoic anhydride (37.2 g, 0.165 M) was added with stirring. After stirring for 3 hours, TLC showed the reaction to be approximately 95% complete. The solvent was evaporated and the residue azeotroped with MeOH (200 mL). The residue was dissolved in  $\text{CHCl}_3$  (700 mL) and extracted with saturated  $\text{NaHCO}_3$  (2x300 mL) and saturated  $\text{NaCl}$  (2x300 mL), dried over  $\text{MgSO}_4$  and evaporated to give a residue (96 g). The residue was chromatographed on a 1.5 kg silica column using  $\text{EtOAc}$ /hexane (1:1) containing 0.5%  $\text{Et}_3\text{NH}$  as the eluting solvent. The pure product fractions were evaporated to give 90 g (90%) of the title compound.

**N4-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine-3'-amidite**

N4-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine (74 g, 0.10 M) was dissolved in  $\text{CH}_2\text{Cl}_2$  (1 L). Tetrazole diisopropylamine (7.1 g) and 2-cyanoethoxy-tetra(isopropyl)-phosphite (40.5 mL, 0.123 M) were added with stirring, under a nitrogen atmosphere. The resulting mixture was stirred for 20 hours at room temperature (TLC showed the reaction to be 95% complete). The reaction mixture was extracted with saturated  $\text{NaHCO}_3$  (1x300 mL) and saturated  $\text{NaCl}$  (3x300 mL). The aqueous washes were back-extracted with  $\text{CH}_2\text{Cl}_2$  (300 mL), and the extracts were combined, dried over  $\text{MgSO}_4$  and concentrated. The residue obtained was chromatographed on a 1.5 kg silica column using  $\text{EtOAc}$ /hexane (3:1) as the eluting solvent. The pure fractions were combined to give 90.6 g (87%) of the title compound.

**2'-O-(Aminooxyethyl) nucleoside amidites and 2'-O-(dimethylaminooxyethyl) nucleoside amidites**

**2'-(Dimethylaminooxyethoxy) nucleoside amidites**

2'-(Dimethylaminooxyethoxy) nucleoside amidites [also known in the art as 2'-O-(dimethylaminooxyethyl) nucleoside amidites] are prepared as described in the following paragraphs. Adenosine, cytidine and guanosine nucleoside amidites are prepared similarly to the thymidine (5-methyluridine) except the exocyclic amines are protected with a benzoyl moiety in the case

-56-

of adenosine and cytidine and with isobutyryl in the case of guanosine.

**5'-O-tert-Butyldiphenylsilyl-O<sup>2</sup>-2'-anhydro-5-methyluridine**

5        O<sup>2</sup>-2'-anhydro-5-methyluridine (Pro. Bio. Sint., Varese, Italy, 100.0g, 0.416 mmol), dimethylaminopyridine (0.66g, 0.013eq, 0.0054mmol) were dissolved in dry pyridine (500 ml) at ambient temperature under an argon atmosphere and with mechanical stirring. *tert*-Butyldiphenylchlorosilane (125.8g, 10 119.0mL, 1.1eq, 0.458mmol) was added in one portion. The reaction was stirred for 16 h at ambient temperature. TLC (Rf 0.22, ethyl acetate) indicated a complete reaction. The solution was concentrated under reduced pressure to a thick oil. This was partitioned between dichloromethane (1 L) and saturated 15 sodium bicarbonate (2x1 L) and brine (1 L). The organic layer was dried over sodium sulfate and concentrated under reduced pressure to a thick oil. The oil was dissolved in a 1:1 mixture of ethyl acetate and ethyl ether (600mL) and the solution was cooled to 20 -10°C. The resulting crystalline product was collected by filtration, washed with ethyl ether (3x200 mL) and dried (40°C, 1mm Hg, 24 h) to 149g (74.8%) of white solid. TLC and NMR were consistent with pure product.

25        **5'-O-tert-Butyldiphenylsilyl-2'-O-(2-hydroxyethyl)-5-methyluridine**

In a 2 L stainless steel, unstirred pressure reactor was added borane in tetrahydrofuran (1.0 M, 2.0 eq, 622 mL). In the fume hood and with manual stirring, ethylene glycol (350 mL, 30 excess) was added cautiously at first until the evolution of hydrogen gas subsided. 5'-O-tert-Butyldiphenylsilyl-O<sup>2</sup>-2'-anhydro-5-methyluridine (149 g, 0.311 mol) and sodium bicarbonate (0.074 g, 0.003 eq) were added with manual stirring. The reactor was sealed and heated in an oil bath until an 35 internal temperature of 160 °C was reached and then maintained for 16 h (pressure < 100 psig). The reaction vessel was cooled to ambient and opened. TLC (Rf 0.67 for desired product and Rf 0.82 for ara-T side product, ethyl acetate) indicated about 70%

-57-

conversion to the product. In order to avoid additional side product formation, the reaction was stopped, concentrated under reduced pressure (10 to 1mm Hg) in a warm water bath (40-100°C) with the more extreme conditions used to remove the ethylene glycol. [Alternatively, once the low boiling solvent is gone, the remaining solution can be partitioned between ethyl acetate and water. The product will be in the organic phase.] The residue was purified by column chromatography (2kg silica gel, ethyl acetate-hexanes gradient 1:1 to 4:1). The appropriate fractions were combined, stripped and dried to product as a white crisp foam (84g, 50%), contaminated starting material (17.4g) and pure reusable starting material 20g. The yield based on starting material less pure recovered starting material was 58%. TLC and NMR were consistent with 99% pure product.

**2'-O-([2-phthalimidoxy)ethyl]-5'-t-butylldiphenylsilyl-5-methyluridine**

5'-O-tert-Butylldiphenylsilyl-2'-O-(2-hydroxyethyl)-5-methyluridine (20g, 36.98mmol) was mixed with triphenylphosphine (11.63g, 44.36mmol) and N-hydroxyphthalimide (7.24g, 44.36mmol). It was then dried over P<sub>2</sub>O<sub>5</sub> under high vacuum for two days at 40°C. The reaction mixture was flushed with argon and dry THF (369.8mL, Aldrich, sure seal bottle) was added to get a clear solution. Diethyl-azodicarboxylate (6.98mL, 44.36mmol) was added dropwise to the reaction mixture. The rate of addition is maintained such that resulting deep red coloration is just discharged before adding the next drop. After the addition was complete, the reaction was stirred for 4 hrs. By that time TLC showed the completion of the reaction (ethylacetate:hexane, 60:40). The solvent was evaporated in vacuum. Residue obtained was placed on a flash column and eluted with ethyl acetate:hexane (60:40), to get 2'-O-([2-phthalimidoxy)ethyl]-5'-t-butylldiphenylsilyl-5-methyluridine as white foam (21.819 g, 86%).

-58-

**5'-O-tert-butyldiphenylsilyl-2'-O-[(2-formadoximinooxy)ethyl]-5-methyluridine**

2'-O-([2-phthalimidooxy)ethyl]-5'-t-butyldiphenylsilyl-5-methyluridine (3.1g, 4.5mmol) was dissolved in dry  $\text{CH}_2\text{Cl}_2$  (4.5mL) and methylhydrazine (300mL, 4.64mmol) was added dropwise at  $-10^\circ\text{C}$  to  $0^\circ\text{C}$ . After 1 h the mixture was filtered, the filtrate was washed with ice cold  $\text{CH}_2\text{Cl}_2$  and the combined organic phase was washed with water, brine and dried over anhydrous  $\text{Na}_2\text{SO}_4$ . The solution was concentrated to get 2'-O-(aminooxyethyl) thymidine, which was then dissolved in MeOH (67.5mL). To this formaldehyde (20% aqueous solution, w/w, 1.1 eq.) was added and the resulting mixture was stirred for 1 h. Solvent was removed under vacuum; residue chromatographed to get 5'-O-tert-butyldiphenylsilyl-2'-O-[(2-formadoximinooxy) ethyl]-5-methyluridine as white foam (1.95 g, 78%).

**5'-O-tert-Butyldiphenylsilyl-2'-O-[N,N-dimethylaminooxyethyl]-5-methyluridine**

5'-O-tert-butyldiphenylsilyl-2'-O-[(2-formadoximinooxy)ethyl]-5-methyluridine (1.77g, 3.12mmol) was dissolved in a solution of 1M pyridinium p-toluenesulfonate (PPTS) in dry MeOH (30.6mL). Sodium cyanoborohydride (0.39g, 6.13mmol) was added to this solution at  $10^\circ\text{C}$  under inert atmosphere. The reaction mixture was stirred for 10 minutes at  $10^\circ\text{C}$ . After that the reaction vessel was removed from the ice bath and stirred at room temperature for 2 h, the reaction monitored by TLC (5% MeOH in  $\text{CH}_2\text{Cl}_2$ ). Aqueous  $\text{NaHCO}_3$  solution (5%, 10mL) was added and extracted with ethyl acetate (2x20mL). Ethyl acetate phase was dried over anhydrous  $\text{Na}_2\text{SO}_4$ , evaporated to dryness. Residue was dissolved in a solution of 1M PPTS in MeOH (30.6mL). Formaldehyde (20% w/w, 30mL, 3.37mmol) was added and the reaction mixture was stirred at room temperature for 10 minutes. Reaction mixture cooled to  $10^\circ\text{C}$  in an ice bath, sodium cyanoborohydride (0.39g, 6.13mmol) was added and reaction mixture stirred at  $10^\circ\text{C}$  for 10 minutes. After 10 minutes, the reaction mixture was removed from the ice bath and stirred at room temperature for 2 hrs. To the reaction mixture 5%  $\text{NaHCO}_3$

-59-

(25mL) solution was added and extracted with ethyl acetate (2x25mL). Ethyl acetate layer was dried over anhydrous  $\text{Na}_2\text{SO}_4$  and evaporated to dryness. The residue obtained was purified by flash column chromatography and eluted with 5% MeOH in  $\text{CH}_2\text{Cl}_2$  to get 5'-O-*tert*-butyldiphenylsilyl-2'-O-[N,N-dimethylaminoxyethyl]-5-methyluridine as a white foam (14.6g, 80%).

**2'-O-(dimethylaminoxyethyl)-5-methyluridine**

Triethylamine trihydrofluoride (3.91mL, 24.0mmol) was dissolved in dry THF and triethylamine (1.67mL, 12mmol, dry, kept over KOH). This mixture of triethylamine-2HF was then added to 5'-O-*tert*-butyldiphenylsilyl-2'-O-[N,N-dimethylaminoxyethyl]-5-methyluridine (1.40g, 2.4mmol) and stirred at room temperature for 24 hrs. Reaction was monitored by TLC (5% MeOH in  $\text{CH}_2\text{Cl}_2$ ). Solvent was removed under vacuum and the residue placed on a flash column and eluted with 10% MeOH in  $\text{CH}_2\text{Cl}_2$  to get 2'-O-(dimethylaminoxyethyl)-5-methyluridine (766mg, 92.5%).

**5'-O-DMT-2'-O-(dimethylaminoxyethyl)-5-methyluridine**

2'-O-(dimethylaminoxyethyl)-5-methyluridine (750mg, 2.17mmol) was dried over  $\text{P}_2\text{O}_5$  under high vacuum overnight at 40°C. It was then co-evaporated with anhydrous pyridine (20mL). The residue obtained was dissolved in pyridine (11mL) under argon atmosphere. 4-dimethylaminopyridine (26.5mg, 2.60mmol), 4,4'-dimethoxytrityl chloride (880mg, 2.60mmol) was added to the mixture and the reaction mixture was stirred at room temperature until all of the starting material disappeared. Pyridine was removed under vacuum and the residue chromatographed and eluted with 10% MeOH in  $\text{CH}_2\text{Cl}_2$  (containing a few drops of pyridine) to get 5'-O-DMT-2'-O-(dimethylamino-oxyethyl)-5-methyluridine (1.13g, 80%).

**5'-O-DMT-2'-O-(2-N,N-dimethylaminoxyethyl)-5-methyluridine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite]**

-60-

5'-O-DMT-2'-O-(dimethylaminoxyethyl)-5-methyluridine (1.08g, 1.67mmol) was co-evaporated with toluene (20mL). To the residue N,N-diisopropylamine tetrazonide (0.29g, 1.67mmol) was added and dried over P<sub>2</sub>O<sub>5</sub> under high vacuum overnight at 40°C.

5 Then the reaction mixture was dissolved in anhydrous acetonitrile (8.4mL) and 2-cyanoethyl-N,N,N<sup>1</sup>,N<sup>1</sup>-tetraisopropylphosphoramidite (2.12mL, 6.08mmol) was added. The reaction mixture was stirred at ambient temperature for 4 hrs under inert atmosphere. The progress of the reaction was  
10 monitored by TLC (hexane:ethyl acetate 1:1). The solvent was evaporated, then the residue was dissolved in ethyl acetate (70mL) and washed with 5% aqueous NaHCO<sub>3</sub> (40mL). Ethyl acetate layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated. Residue obtained was chromatographed (ethyl acetate as eluent) to get  
15 5'-O-DMT-2'-O-(2-N,N-dimethylaminoxyethyl)-5-methyluridine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite] as a foam (1.04g, 74.9%).

#### **2'-(Aminooxyethoxy) nucleoside amidites**

20 2'-(Aminooxyethoxy) nucleoside amidites [also known in the art as 2'-O-(aminooxyethyl) nucleoside amidites] are prepared as described in the following paragraphs. Adenosine, cytidine and thymidine nucleoside amidites are prepared similarly.

#### **25 N2-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite]**

The 2'-O-aminooxyethyl guanosine analog may be obtained by selective 2'-O-alkylation of diaminopurine riboside. Multigram  
30 quantities of diaminopurine riboside may be purchased from Schering AG (Berlin) to provide 2'-O-(2-ethylacetyl) diaminopurine riboside along with a minor amount of the 3'-O-isomer. 2'-O-(2-ethylacetyl) diaminopurine riboside may be resolved and converted to 2'-O-(2-ethylacetyl)guanosine by  
35 treatment with adenosine deaminase. (McGee, D. P. C., Cook, P. D., Guinosso, C. J., WO 94/02501 A1 940203.) Standard protection procedures should afford 2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine and 2-N-isobutyryl-6-O-

-61-

diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine which may be reduced to provide 2-N-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-hydroxyethyl)-5'-O-(4,4'-dimethoxytrityl)guanosine. As before the hydroxyl group may be displaced by N-hydroxyphthalimide via a Mitsunobu reaction, and the protected nucleoside may be phosphorylated as usual to yield 2-N-isobutyryl-6-O-diphenylcarbamoyl-2'-O-([2-phthalamidoxy]ethyl)-5'-O-(4,4'-dimethoxytrityl)guanosine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite].

#### **2'-dimethylaminoethoxyethoxy (2'-DMAEOE) nucleoside amidites**

2'-dimethylaminoethoxyethoxy nucleoside amidites (also known in the art as 2'-O-dimethylaminoethoxyethyl, i.e., 2'-O-CH<sub>2</sub>-O-CH<sub>2</sub>-N(CH<sub>2</sub>)<sub>2</sub>, or 2'-DMAEOE nucleoside amidites) are prepared as follows. Other nucleoside amidites are prepared similarly.

#### **2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine**

2[2-(Dimethylamino)ethoxy]ethanol (Aldrich, 6.66 g, 50 mmol) is slowly added to a solution of borane in tetrahydrofuran (1 M, 10 mL, 10 mmol) with stirring in a 100 mL bomb. Hydrogen gas evolves as the solid dissolves. O<sup>2</sup>-,2'-anhydro-5-methyluridine (1.2 g, 5 mmol), and sodium bicarbonate (2.5 mg) are added and the bomb is sealed, placed in an oil bath and heated to 155°C for 26 hours. The bomb is cooled to room temperature and opened. The crude solution is concentrated and the residue partitioned between water (200 mL) and hexanes (200 mL). The excess phenol is extracted into the hexane layer. The aqueous layer is extracted with ethyl acetate (3x200 mL) and the combined organic layers are washed once with water, dried over anhydrous sodium sulfate and concentrated. The residue is columned on silica gel using methanol/methylene chloride 1:20 (which has 2% triethylamine) as the eluent. As the column fractions are concentrated a colorless solid forms which is collected to give the title compound as a white solid.

#### **5'-O-dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine**

-62-

To 0.5 g (1.3 mmol) of 2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine in anhydrous pyridine (8 mL), triethylamine (0.36 mL) and dimethoxytrityl chloride (DMT-Cl, 0.87 g, 2 eq.) are added and stirred for 1 hour. The reaction mixture is poured into water (200 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (2x200 mL). The combined CH<sub>2</sub>Cl<sub>2</sub> layers are washed with saturated NaHCO<sub>3</sub> solution, followed by saturated NaCl solution and dried over anhydrous sodium sulfate. Evaporation of the solvent followed by silica gel chromatography using MeOH:CH<sub>2</sub>Cl<sub>2</sub>:Et<sub>3</sub>N (20:1, v/v, with 1% triethylamine) gives the title compound.

**5'-O-Dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine-3'-O-(cyanoethyl-N,N-diisopropyl)phosphoramidite**

Diisopropylaminotetrazolide (0.6 g) and 2-cyanoethoxy-N,N-diisopropyl phosphoramidite (1.1 mL, 2 eq.) are added to a solution of 5'-O-dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyluridine (2.17 g, 3 mmol) dissolved in CH<sub>2</sub>Cl<sub>2</sub> (20 mL) under an atmosphere of argon. The reaction mixture is stirred overnight and the solvent evaporated. The resulting residue is purified by silica gel flash column chromatography with ethyl acetate as the eluent to give the title compound.

**Example 2**

**Oligonucleotide synthesis**

Unsubstituted and substituted phosphodiester (P=O) oligonucleotides are synthesized on an automated DNA synthesizer (Applied Biosystems model 380B) using standard phosphoramidite chemistry with oxidation by iodine.

Phosphorothioates (P=S) are synthesized as for the phosphodiester oligonucleotides except the standard oxidation bottle was replaced by 0.2 M solution of 3H-1,2-benzodithiole-3-one 1,1-dioxide in acetonitrile for the stepwise thiation of the phosphite linkages. The thiation wait step was increased to 68 sec and was followed by the capping step. After cleavage from the CPG column and deblocking in concentrated ammonium hydroxide at 55°C (18 h), the oligonucleotides were purified by

-63-

precipitating twice with 2.5 volumes of ethanol from a 0.5 M NaCl solution. Phosphinate oligonucleotides are prepared as described in U.S. Patent 5,508,270, herein incorporated by reference.

5 Alkyl phosphonate oligonucleotides are prepared as described in U.S. Patent 4,469,863, herein incorporated by reference.

3'-Deoxy-3'-methylene phosphonate oligonucleotides are prepared as described in U.S. Patents 5,610,289 or 5,625,050, 10 herein incorporated by reference.

Phosphoramidite oligonucleotides are prepared as described in U.S. Patent, 5,256,775 or U.S. Patent 5,366,878, herein incorporated by reference.

15 Alkylphosphonothioate oligonucleotides are prepared as described in published PCT applications PCT/US94/00902 and PCT/US93/06976 (published as WO 94/17093 and WO 94/02499, respectively), herein incorporated by reference.

3'-Deoxy-3'-amino phosphoramidate oligonucleotides are prepared as described in U.S. Patent 5,476,925, herein 20 incorporated by reference.

Phosphotriester oligonucleotides are prepared as described in U.S. Patent 5,023,243, herein incorporated by reference.

Borano phosphate oligonucleotides are prepared as described in U.S. Patents 5,130,302 and 5,177,198, both herein 25 incorporated by reference.

### Example 3

#### Oligonucleoside Synthesis

Methylenemethylimino linked oligonucleosides, also 30 identified as MMI linked oligonucleosides, methylenedimethylhydrazo linked oligonucleosides, also identified as MDH linked oligonucleosides, and methylenecarbonylamino linked oligonucleosides, also identified as amide-3 linked oligonucleosides, and methyleneaminocarbonyl linked oligo- 35 nucleosides, also identified as amide-4 linked oligonucleosides, as well as mixed backbone compounds having, for instance, alternating MMI and P=O or P=S linkages are prepared as described in U.S. Patents 5,378,825, 5,386,023, 5,489,677,

-64-

5,602,240 and 5,610,289, all of which are herein incorporated by reference.

Formacetal and thioformacetal linked oligonucleosides are prepared as described in U.S. Patents 5,264,562 and 5,264,564,  
5 herein incorporated by reference.

Ethylene oxide linked oligonucleosides are prepared as described in U.S. Patent 5,223,618, herein incorporated by reference.

#### 10 **Example 4**

##### **PNA Synthesis**

Peptide nucleic acids (PNAs) are prepared in accordance with any of the various procedures referred to in Peptide Nucleic Acids (PNA): Synthesis, Properties and Potential  
15 Applications, *Bioorganic & Medicinal Chemistry*, **1996**, 4, 5-23. They may also be prepared in accordance with U.S. Patents 5,539,082, 5,700,922, and 5,719,262, herein incorporated by reference.

#### 20 **Example 5**

##### **Synthesis of Chimeric Oligonucleotides**

Chimeric oligonucleotides, oligonucleosides or mixed oligonucleotides/oligonucleosides of the invention can be of several different types. These include a first type wherein the  
25 "gap" segment of linked nucleosides is positioned between 5' and 3' "wing" segments of linked nucleosides and a second "open end" type wherein the "gap" segment is located at either the 3' or the 5' terminus of the oligomeric compound. Oligonucleotides of the first type are also known in the art as "gapmers" or gapped  
30 oligonucleotides. Oligonucleotides of the second type are also known in the art as "hemimers" or "wingmers".

##### **[2'-O-Me]--[2'-deoxy]--[2'-O-Me] Chimeric Phosphorothioate Oligonucleotides**

Chimeric oligonucleotides having 2'-O-alkyl  
35 phosphorothioate and 2'-deoxy phosphorothioate oligonucleotide segments are synthesized using an Applied Biosystems automated DNA synthesizer Model 380B, as above. Oligonucleotides are synthesized using the automated synthesizer and 2'-deoxy-5'-

-65-

dimethoxytrityl-3'-O-phosphoramidite for the DNA portion and 5'-dimethoxytrityl-2'-O-methyl-3'-O-phosphoramidite for 5' and 3' wings. The standard synthesis cycle is modified by increasing the wait step after the delivery of tetrazole and base to 600 s repeated four times for RNA and twice for 2'-O-methyl. The fully protected oligonucleotide is cleaved from the support and the phosphate group is deprotected in 3:1 ammonia/ethanol at room temperature overnight then lyophilized to dryness. Treatment in methanolic ammonia for 24 hrs at room temperature is then done to deprotect all bases and sample was again lyophilized to dryness. The pellet is resuspended in 1M TBAF in THF for 24 hrs at room temperature to deprotect the 2' positions. The reaction is then quenched with 1M TEAA and the sample is then reduced to 1/2 volume by rotovac before being desalted on a G25 size exclusion column. The oligo recovered is then analyzed spectrophotometrically for yield and for purity by capillary electrophoresis and by mass spectrometry.

**[2'-O-(2-Methoxyethyl)]--[2'-deoxy]--[2'-O-(Methoxyethyl)]**  
**Chimeric Phosphorothioate Oligonucleotides**  
[2'-O-(2-methoxyethyl)]--[2'-deoxy]--[2'-O-(methoxyethyl)]  
chimeric phosphorothioate oligonucleotides were prepared as per the procedure above for the 2'-O-methyl chimeric oligonucleotide, with the substitution of 2'-O-(methoxyethyl) amidites for the 2'-O-methyl amidites.

**[2'-O-(2-Methoxyethyl)Phosphodiester]--[2'-deoxy Phosphorothioate]--[2'-O-(2-Methoxyethyl) Phosphodiester] Chimeric Oligonucleotides**  
[2'-O-(2-methoxyethyl phosphodiester)]--[2'-deoxy phosphorothioate]--[2'-O-(methoxyethyl) phosphodiester] chimeric oligonucleotides are prepared as per the above procedure for the 2'-O-methyl chimeric oligonucleotide with the substitution of 2'-O-(methoxyethyl) amidites for the 2'-O-methyl amidites, oxidization with iodine to generate the phosphodiester internucleotide linkages within the wing portions of the chimeric structures and sulfurization utilizing 3,4-dihydro-2H-benzodithiole-3-one 1,1 dioxide (Beaucage Reagent) to generate

-66-

the phosphorothioate internucleotide linkages for the center gap.

Other chimeric oligonucleotides, chimeric oligonucleosides and mixed chimeric oligonucleotides/oligonucleosides are synthesized according to United States patent 5,623,065, herein incorporated by reference.

#### **Example 6**

##### **Oligonucleotide Isolation**

After cleavage from the controlled pore glass column (Applied Biosystems) and deblocking in concentrated ammonium hydroxide at 55°C for 18 hours, the oligonucleotides or oligonucleosides are purified by precipitation twice out of 0.5 M NaCl with 2.5 volumes ethanol. Synthesized oligonucleotides were analyzed by polyacrylamide gel electrophoresis on denaturing gels and judged to be at least 85% full length material. The relative amounts of phosphorothioate and phosphodiester linkages obtained in synthesis were periodically checked by <sup>31</sup>P nuclear magnetic resonance spectroscopy, and for some studies oligonucleotides were purified by HPLC, as described by Chiang et al., *J. Biol. Chem.* **1991**, 266, 18162-18171. Results obtained with HPLC-purified material were similar to those obtained with non-HPLC purified material.

#### **Example 7**

##### **Oligonucleotide Synthesis - 96 Well Plate Format**

Oligonucleotides were synthesized via solid phase P(III) phosphoramidite chemistry on an automated synthesizer capable of assembling 96 sequences simultaneously in a standard 96 well format. Phosphodiester internucleotide linkages were afforded by oxidation with aqueous iodine. Phosphorothioate internucleotide linkages were generated by sulfurization utilizing 3,4-dithiolane-2-thione 1,1-dioxide (Beaucage Reagent) in anhydrous acetonitrile. Standard base-protected beta-cyanoethyldiisopropyl phosphoramidites were purchased from commercial vendors (e.g. PE-Applied Biosystems, Foster City, CA, or Pharmacia, Piscataway, NJ). Non-standard nucleosides are synthesized as per known literature or patented methods. They

-67-

are utilized as base protected beta-cyanoethyldiisopropyl phosphoramidites.

Oligonucleotides were cleaved from support and deprotected with concentrated  $\text{NH}_4\text{OH}$  at elevated temperature (55-60°C) for 12-16 hours and the released product then dried in vacuo. The dried product was then re-suspended in sterile water to afford a master plate from which all analytical and test plate samples are then diluted utilizing robotic pipettors.

#### 10 **Example 8**

##### **Oligonucleotide Analysis - 96 Well Plate Format**

The concentration of oligonucleotide in each well was assessed by dilution of samples and UV absorption spectroscopy. The full-length integrity of the individual products was evaluated by capillary electrophoresis (CE) in either the 96 well format (Beckman P/ACE™ MDQ) or, for individually prepared samples, on a commercial CE apparatus (e.g., Beckman P/ACE™ 5000, ABI 270). Base and backbone composition was confirmed by mass analysis of the compounds utilizing electrospray-mass spectroscopy. All assay test plates were diluted from the master plate using single and multi-channel robotic pipettors. Plates were judged to be acceptable if at least 85% of the compounds on the plate were at least 85% full length.

#### 25 **Example 9**

##### **Cell culture and oligonucleotide treatment**

The effect of antisense compounds on target nucleic acid expression can be tested in any of a variety of cell types provided that the target nucleic acid is present at measurable levels. This can be routinely determined using, for example, PCR or Northern blot analysis. The following 4 cell types are provided for illustrative purposes, but other cell types can be routinely used, provided that the target is expressed in the cell type chosen. This can be readily determined by methods routine in the art, for example Northern blot analysis, Ribonuclease protection assays, or RT-PCR.

T-24 cells:

-68-

The human transitional cell bladder carcinoma cell line T-24 was obtained from the American Type Culture Collection (ATCC) (Manassas, VA). T-24 cells were routinely cultured in complete McCoy's 5A basal media (Gibco/Life Technologies, Gaithersburg, MD) supplemented with 10% fetal calf serum (Gibco/Life Technologies, Gaithersburg, MD), penicillin 100 units per mL, and streptomycin 100 micrograms per mL (Gibco/Life Technologies, Gaithersburg, MD). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of 7000 cells/well for use in RT-PCR analysis.

For Northern blotting or other analysis, cells may be seeded onto 100 mm or other standard tissue culture plates and treated similarly, using appropriate volumes of medium and oligonucleotide.

#### A549 cells:

The human lung carcinoma cell line A549 was obtained from the American Type Culture Collection (ATCC) (Manassas, VA). A549 cells were routinely cultured in DMEM basal media (Gibco/Life Technologies, Gaithersburg, MD) supplemented with 10% fetal calf serum (Gibco/Life Technologies, Gaithersburg, MD), penicillin 100 units per mL, and streptomycin 100 micrograms per mL (Gibco/Life Technologies, Gaithersburg, MD). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence.

#### NHDF cells:

Human neonatal dermal fibroblast (NHDF) were obtained from the Clonetics Corporation (Walkersville MD). NHDFs were routinely maintained in Fibroblast Growth Medium (Clonetics Corporation, Walkersville MD) supplemented as recommended by the supplier. Cells were maintained for up to 10 passages as recommended by the supplier.

#### HEK cells:

Human embryonic keratinocytes (HEK) were obtained from the Clonetics Corporation (Walkersville MD). HEKs were routinely

-69-

maintained in Keratinocyte Growth Medium (Clonetics Corporation, Walkersville MD) formulated as recommended by the supplier. Cells were routinely maintained for up to 10 passages as recommended by the supplier.

5

Treatment with antisense compounds:

When cells reached 80% confluency, they were treated with oligonucleotide. For cells grown in 96-well plates, wells were washed once with 200  $\mu$ L OPTI-MEM™-1 reduced-serum medium (Gibco BRL) and then treated with 130  $\mu$ L of OPTI-MEM™-1 containing 3.75  $\mu$ g/mL LIPOFECTIN™ (Gibco BRL) and the desired concentration of oligonucleotide. After 4-7 hours of treatment, the medium was replaced with fresh medium. Cells were harvested 16-24 hours after oligonucleotide treatment.

15 The concentration of oligonucleotide used varies from cell line to cell line. To determine the optimal oligonucleotide concentration for a particular cell line, the cells are treated with a positive control oligonucleotide at a range of concentrations. For human cells the positive control oligonucleotide is ISIS 13920, **TCCGTCATCGCTCCTCAGGG**, SEQ ID NO: 1, a 2'-O-methoxyethyl gapmer (2'-O-methoxyethyls shown in bold) with a phosphorothioate backbone which is targeted to human H-ras. For mouse or rat cells the positive control oligonucleotide is ISIS 15770, **ATGCATTCTGCCCCCAAGGA**, SEQ ID NO: 2, a 2'-O-methoxyethyl gapmer (2'-O-methoxyethyls shown in bold) with a phosphorothioate backbone which is targeted to both mouse and rat c-raf. The concentration of positive control oligonucleotide that results in 80% inhibition of c-Ha-ras (for ISIS 13920) or c-raf (for ISIS 15770) mRNA is then utilized as the screening concentration for new oligonucleotides in subsequent experiments for that cell line. If 80% inhibition is not achieved, the lowest concentration of positive control oligonucleotide that results in 60% inhibition of H-ras or c-raf mRNA is then utilized as the oligonucleotide screening concentration in subsequent experiments for that cell line. If 60% inhibition is not achieved, that particular cell line is deemed as unsuitable for oligonucleotide transfection

experiments.

-71-

**Example 10****Analysis of oligonucleotide inhibition of fibroblast growth factor receptor 3 expression**

5        Antisense modulation of fibroblast growth factor receptor 3 expression can be assayed in a variety of ways known in the art. For example, fibroblast growth factor receptor 3 mRNA levels can be quantitated by, e.g., Northern blot analysis, competitive polymerase chain reaction (PCR), or real-time PCR (RT-PCR).  
10    Real-time quantitative PCR is presently preferred. RNA analysis can be performed on total cellular RNA or poly(A)+ mRNA. Methods of RNA isolation are taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.1.1-4.2.9 and 4.5.1-4.5.3, John Wiley & Sons, Inc., **1993**.  
15    Northern blot analysis is routine in the art and is taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.2.1-4.2.9, John Wiley & Sons, Inc., **1996**. Real-time quantitative (PCR) can be conveniently accomplished using the commercially available ABI PRISM™ 7700  
20    Sequence Detection System, available from PE-Applied Biosystems, Foster City, CA and used according to manufacturer's instructions.

      Protein levels of fibroblast growth factor receptor 3 can be quantitated in a variety of ways well known in the art, such  
25    as immunoprecipitation, Western blot analysis (immunoblotting), ELISA or fluorescence-activated cell sorting (FACS). Antibodies directed to fibroblast growth factor receptor 3 can be identified and obtained from a variety of sources, such as the MSRS catalog of antibodies (Aerie Corporation, Birmingham, MI),  
30    or can be prepared via conventional antibody generation methods. Methods for preparation of polyclonal antisera are taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 11.12.1-11.12.9, John Wiley & Sons, Inc., **1997**. Preparation of monoclonal antibodies is  
35    taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 11.4.1-11.11.5, John Wiley & Sons, Inc., **1997**.

      Immunoprecipitation methods are standard in the art and can

-72-

be found at, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 10.16.1-10.16.11, John Wiley & Sons, Inc., **1998**. Western blot (immunoblot) analysis is standard in the art and can be found at, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 10.8.1-10.8.21, John Wiley & Sons, Inc., **1997**. Enzyme-linked immunosorbent assays (ELISA) are standard in the art and can be found at, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 11.2.1-11.2.22, John Wiley & Sons, Inc., **1991**.

**Example 11****Poly(A)+ mRNA isolation**

Poly(A)+ mRNA was isolated according to Miura et al., *Clin. Chem.*, **1996**, 42, 1758-1764. Other methods for poly(A)+ mRNA isolation are taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.5.1-4.5.3, John Wiley & Sons, Inc., **1993**. Briefly, for cells grown on 96-well plates, growth medium was removed from the cells and each well was washed with 200  $\mu$ L cold PBS. 60  $\mu$ L lysis buffer (10 mM Tris-HCl, pH 7.6, 1 mM EDTA, 0.5 M NaCl, 0.5% NP-40, 20 mM vanadyl-ribonucleoside complex) was added to each well, the plate was gently agitated and then incubated at room temperature for five minutes. 55  $\mu$ L of lysate was transferred to Oligo d(T) coated 96-well plates (AGCT Inc., Irvine CA). Plates were incubated for 60 minutes at room temperature, washed 3 times with 200  $\mu$ L of wash buffer (10 mM Tris-HCl pH 7.6, 1 mM EDTA, 0.3 M NaCl). After the final wash, the plate was blotted on paper towels to remove excess wash buffer and then air-dried for 5 minutes. 60  $\mu$ L of elution buffer (5 mM Tris-HCl pH 7.6), preheated to 70°C was added to each well, the plate was incubated on a 90°C hot plate for 5 minutes, and the eluate was then transferred to a fresh 96-well plate.

Cells grown on 100 mm or other standard plates may be treated similarly, using appropriate volumes of all solutions.

**Example 12**

-73-

**Total RNA Isolation**

Total RNA was isolated using an RNEASY 96™ kit and buffers purchased from Qiagen Inc. (Valencia CA) following the manufacturer's recommended procedures. Briefly, for cells grown on 96-well plates, growth medium was removed from the cells and each well was washed with 200 µL cold PBS. 100 µL Buffer RLT was added to each well and the plate vigorously agitated for 20 seconds. 100 µL of 70% ethanol was then added to each well and the contents mixed by pipetting three times up and down. The samples were then transferred to the RNEASY 96™ well plate attached to a QIAVAC™ manifold fitted with a waste collection tray and attached to a vacuum source. Vacuum was applied for 15 seconds. 1 mL of Buffer RW1 was added to each well of the RNEASY 96™ plate and the vacuum again applied for 15 seconds. 1 mL of Buffer RPE was then added to each well of the RNEASY 96™ plate and the vacuum applied for a period of 15 seconds. The Buffer RPE wash was then repeated and the vacuum was applied for an additional 10 minutes. The plate was then removed from the QIAVAC™ manifold and blotted dry on paper towels. The plate was then re-attached to the QIAVAC™ manifold fitted with a collection tube rack containing 1.2 mL collection tubes. RNA was then eluted by pipetting 60 µL water into each well, incubating 1 minute, and then applying the vacuum for 30 seconds. The elution step was repeated with an additional 60 µL water.

The repetitive pipetting and elution steps may be automated using a QIAGEN Bio-Robot 9604 (Qiagen, Inc., Valencia CA). Essentially, after lysing of the cells on the culture plate, the plate is transferred to the robot deck where the pipetting, DNase treatment and elution steps are carried out.

**Example 13****Real-time Quantitative PCR Analysis of fibroblast growth factor receptor 3 mRNA Levels**

Quantitation of fibroblast growth factor receptor 3 mRNA

-74-

levels was determined by real-time quantitative PCR using the ABI PRISM™ 7700 Sequence Detection System (PE-Applied Biosystems, Foster City, CA) according to manufacturer's instructions. This is a closed-tube, non-gel-based, fluorescence detection system which allows high-throughput quantitation of polymerase chain reaction (PCR) products in real-time. As opposed to standard PCR, in which amplification products are quantitated after the PCR is completed, products in real-time quantitative PCR are quantitated as they accumulate. This is accomplished by including in the PCR reaction an oligonucleotide probe that anneals specifically between the forward and reverse PCR primers, and contains two fluorescent dyes. A reporter dye (e.g., JOE, FAM, or VIC, obtained from either Operon Technologies Inc., Alameda, CA or PE-Applied Biosystems, Foster City, CA) is attached to the 5' end of the probe and a quencher dye (e.g., TAMRA, obtained from either Operon Technologies Inc., Alameda, CA or PE-Applied Biosystems, Foster City, CA) is attached to the 3' end of the probe. When the probe and dyes are intact, reporter dye emission is quenched by the proximity of the 3' quencher dye. During amplification, annealing of the probe to the target sequence creates a substrate that can be cleaved by the 5'-exonuclease activity of Taq polymerase. During the extension phase of the PCR amplification cycle, cleavage of the probe by Taq polymerase releases the reporter dye from the remainder of the probe (and hence from the quencher moiety) and a sequence-specific fluorescent signal is generated. With each cycle, additional reporter dye molecules are cleaved from their respective probes, and the fluorescence intensity is monitored at regular intervals by laser optics built into the ABI PRISM™ 7700 Sequence Detection System. In each assay, a series of parallel reactions containing serial dilutions of mRNA from untreated control samples generates a standard curve that is used to quantitate the percent inhibition after antisense oligonucleotide treatment of test samples.

Prior to quantitative PCR analysis, primer-probe sets specific to the target gene being measured are evaluated for their ability to be "multiplexed" with a GAPDH amplification

-75-

reaction. In multiplexing, both the target gene and the internal standard gene GAPDH are amplified concurrently in a single sample. In this analysis, mRNA isolated from untreated cells is serially diluted. Each dilution is amplified in the presence of primer-probe sets specific for GAPDH only, target gene only ("single-plexing"), or both (multiplexing). Following PCR amplification, standard curves of GAPDH and target mRNA signal as a function of dilution are generated from both the single-plexed and multiplexed samples. If both the slope and correlation coefficient of the GAPDH and target signals generated from the multiplexed samples fall within 10% of their corresponding values generated from the single-plexed samples, the primer-probe set specific for that target is deemed multiplexable. Other methods of PCR are also known in the art.

PCR reagents were obtained from PE-Applied Biosystems, Foster City, CA. RT-PCR reactions were carried out by adding 25  $\mu$ L PCR cocktail (1x TAQMAN<sup>TM</sup> buffer A, 5.5 mM MgCl<sub>2</sub>, 300  $\mu$ M each of dATP, dCTP and dGTP, 600  $\mu$ M of dUTP, 100 nM each of forward primer, reverse primer, and probe, 20 Units RNase inhibitor, 1.25 Units AMPLITAQ GOLD<sup>TM</sup>, and 12.5 Units MuLV reverse transcriptase) to 96 well plates containing 25  $\mu$ L total RNA solution. The RT reaction was carried out by incubation for 30 minutes at 48°C. Following a 10 minute incubation at 95°C to activate the AMPLITAQ GOLD<sup>TM</sup>, 40 cycles of a two-step PCR protocol were carried out: 95°C for 15 seconds (denaturation) followed by 60°C for 1.5 minutes (annealing/extension).

Gene target quantities obtained by real time RT-PCR are normalized using either the expression level of GAPDH, a gene whose expression is constant, or by quantifying total RNA using RiboGreen<sup>TM</sup> (Molecular Probes, Inc. Eugene, OR). GAPDH expression is quantified by real time RT-PCR, by being run simultaneously with the target, multiplexing, or separately. Total RNA is quantified using RiboGreen<sup>TM</sup> RNA quantification reagent from Molecular Probes. Methods of RNA quantification by RiboGreen<sup>TM</sup> are taught in Jones, L.J., et al, *Analytical Biochemistry*, 1998, 265, 368-374.

-76-

In this assay, 175  $\mu$ L of RiboGreen™ working reagent (RiboGreen™ reagent diluted 1:2865 in 10mM Tris-HCl, 1 mM EDTA, pH 7.5) is pipetted into a 96-well plate containing 25uL purified, cellular RNA. The plate is read in a CytoFluor 4000  
5 (PE Applied Biosystems) with excitation at 480nm and emission at 520nm.

Probes and primers to human fibroblast growth factor receptor 3 were designed to hybridize to a human fibroblast growth factor receptor 3 sequence, using published sequence  
10 information (GenBank accession number M58051, incorporated herein as SEQ ID NO:3). For human fibroblast growth factor receptor 3 the PCR primers were:

forward primer: GGCCATCGGCATTGACA (SEQ ID NO: 4)

reverse primer: GGCATCGTCTTTTCAGCATCTT (SEQ ID NO: 5) and the PCR

15 probe was: FAM-CCGCCAAGCCTGTCACCGTAGC-TAMRA

(SEQ ID NO: 6) where FAM (PE-Applied Biosystems, Foster City, CA) is the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems, Foster City, CA) is the quencher dye. For human GAPDH the PCR primers were:

20 forward primer: GAAGGTGAAGGTCGGAGTC (SEQ ID NO: 7)

reverse primer: GAAGATGGTGATGGGATTTC (SEQ ID NO: 8) and the PCR

probe was: 5' JOE-CAAGCTTCCC GTTCTCAGCC- TAMRA 3' (SEQ ID NO: 9)

where JOE (PE-Applied Biosystems, Foster City, CA) is the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems,  
25 Foster City, CA) is the quencher dye.

#### **Example 14**

#### **Northern blot analysis of fibroblast growth factor receptor 3**

#### **30 mRNA levels**

Eighteen hours after antisense treatment, cell monolayers were washed twice with cold PBS and lysed in 1 mL RNAZOL™ (TEL-TEST "B" Inc., Friendswood, TX). Total RNA was prepared following manufacturer's recommended protocols. Twenty  
35 micrograms of total RNA was fractionated by electrophoresis through 1.2% agarose gels containing 1.1% formaldehyde using a MOPS buffer system (AMRESCO, Inc. Solon, OH). RNA was transferred from the gel to HYBOND™-N+ nylon membranes (Amersham

-77-

Pharmacia Biotech, Piscataway, NJ) by overnight capillary transfer using a Northern/Southern Transfer buffer system (TEL-TEST "B" Inc., Friendswood, TX). RNA transfer was confirmed by UV visualization. Membranes were fixed by UV cross-linking

5 using a STRATALINKER™ UV Crosslinker 2400 (Stratagene, Inc, La Jolla, CA) and then probed using QUICKHYB™ hybridization solution (Stratagene, La Jolla, CA) using manufacturer's recommendations for stringent conditions.

To detect human fibroblast growth factor receptor 3, a

10 human fibroblast growth factor receptor 3 specific probe was prepared by PCR using the forward primer GGCCATCGGCATTGACA (SEQ ID NO: 4) and the reverse primer GGCATCGTCTTTCAGCATCTT (SEQ ID NO: 5). To normalize for variations in loading and transfer efficiency membranes were stripped and probed for human

15 glyceraldehyde-3-phosphate dehydrogenase (GAPDH) RNA (Clontech, Palo Alto, CA).

Hybridized membranes were visualized and quantitated using a PHOSPHORIMAGER™ and IMAGEQUANT™ Software V3.3 (Molecular Dynamics, Sunnyvale, CA). Data was normalized to GAPDH levels

20 in untreated controls.

#### **Example 15**

##### **Antisense inhibition of human fibroblast growth factor receptor**

25 **3 expression by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap**

In accordance with the present invention, a series of oligonucleotides were designed to target different regions of the human fibroblast growth factor receptor 3 RNA, using

30 published sequences (GenBank accession number M58051, incorporated herein as SEQ ID NO: 3, GenBank accession number M64347, incorporated herein as SEQ ID NO: 10, GenBank accession number L78723, incorporated herein as SEQ ID NO: 11, GenBank accession number L78726, incorporated herein as SEQ ID NO: 12,

35 GenBank accession number L78727, incorporated herein as SEQ ID NO: 13, GenBank accession number L78729, incorporated herein as SEQ ID NO: 14, GenBank accession number L78735, incorporated

-78-

herein as SEQ ID NO: 15, GenBank accession number L78736, incorporated herein as SEQ ID NO: 16, and GenBank accession number Y09852, incorporated herein as SEQ ID NO: 17). The oligonucleotides are shown in Table 1. "Target site" indicates the first (5'-most) nucleotide number on the particular target sequence to which the oligonucleotide binds. All compounds in Table 1 are chimeric oligonucleotides ("gapmers") 20 nucleotides in length, composed of a central "gap" region consisting of ten 2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by five-nucleotide "wings". The wings are composed of 2'-methoxyethyl (2'-MOE)nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All cytidine residues are 5-methylcytidines. The compounds were analyzed for their effect on human fibroblast growth factor receptor 3 mRNA levels by quantitative real-time PCR as described in other examples herein. Data are averages from two experiments. If present, "N.D." indicates "no data".

Table 1

Inhibition of human fibroblast growth factor receptor 3 mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap

ISIS #	REGION	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	%INHIB	SEQ ID NO
125105	5'UTR	3	4	gcggcgctcctcaggcagcgc	56	18
125106	Coding	3	82	gaggcgccggccacgatggc	38	19
125108	Coding	3	391	cgcacactgaagtggcacag	63	20
125109	Coding	3	416	tcccaggatggagcgtctg	79	21
125110	Coding	3	426	cttcgtcatctcccaggat	82	22
125112	Coding	3	461	gtccacacctgtgtcctcag	89	23
125113	Coding	3	494	ccgctcgggccgtgtccagt	81	24
125114	Coding	3	590	cttcagccaggagatggagg	75	25
125116	Coding	3	747	gcgtgtacgtctgccggatg	73	26
125118	Coding	3	848	cttgcaagtggaaactccacgt	56	27
125119	Coding	3	917	gccaccttgctgccgttca	63	28
125127	Coding	3	1161	ccccgtagctgaggatgcct	79	29
125128	Coding	3	1288	acctgtcgcttgagcgggaa	55	30
125133	Coding	3	1755	aggagtagtccaggcccg	39	31
125135	Coding	3	1952	gttggtgcacgtcccgccca	43	32
125142	Stop Codon	3	2449	gtggcccttcacgtccgcga	62	33
125143	Coding	10	2211	gggacccctcacattgttgg	53	34
125144	Coding	10	2343	acgcggatgtgcacacacac	64	35
125145	Coding	10	2457	cccagaacaaaggcccctcg	55	36
125146	Coding	10	2534	ccgagccatgtcgggccag	62	37
125147	Coding	10	2572	agcgcaccctgtgatgtccc	81	38

125148	Coding	10	2798	tacacagcatctatatttatag	75	39
125150	Coding	10	2853	taccagccttttcctcttcc	88	40
125151	Coding	10	2870	gtcgcaggcctccgttgtac	78	41
125152	Coding	10	2884	cctgtgccccagggtcgca	65	42
125153	Coding	10	3034	gggcccataaatagctttac	44	43
125154	Coding	10	3121	ggttgtcaataagttaaaaa	43	44
125155	Coding	10	3157	cttggccgtccctctatcgg	78	45
125156	Coding	10	3248	aaaatatcttcactggaatc	44	46
125157	Coding	10	3273	tctcctgaaaaaggacaaag	88	47
125160	Coding	10	3349	atttgtatgaaaataccagc	61	48
125161	Coding	10	3374	cctgggacacacagcaatta	74	49
125162	Coding	10	3424	catcggaacctgcacacagg	91	50
125163	Coding	10	3565	tccaagcttttgaaaggtagc	74	51
125164	Coding	10	3652	atggccctgcaggcaagcaa	0	52
125165	Coding	10	3690	accatgcactgggcccgaag	75	53
125166	Coding	10	3767	agggtgtctttatttttcggga	65	54
125167	Coding	10	3777	gttagcaaccagggtgtcttt	69	55
125168	Intron	11	17	tggaccctgctcctacctgt	74	56
125169	Intron	11	848	ggagcagaggcccctctgaa	51	57
125170	Intron	12	340	ccttgccacactgcctcc	75	58
125171	Intron	12	540	acagatgtttctctttgggc	83	59
125172	Intron	12	567	gcccccaagagaccgtcttc	88	60
125173	Intron	13	373	gcgggttagcgcagagccgg	63	61
125174	Intron	13	556	cacggcaggatccagccgct	80	62
125175	Intron	14	55	gctccaggaggcctggcggg	49	63
125176	Intron	15	208	aggtgaggtcaggctgtcct	60	64
125177	Intron	16	10	agggatgccactcacaggtc	44	65
125178	Intron	17	808	cgccgggctgagctgtgcgc	58	66
125179	Intron	17	895	ccgcgtcgaggtaaaagaa	45	67
125180	Intron	17	2018	ggagacccaagcccctggg	33	68
125181	Intron	17	2560	cctcgggttgacccagaga	75	69
125182	Intron	17	3779	gtgaccctgccagccagaag	77	70
125185	Coding	3	374	cagtacgcgctgcgtgagcc	63	71
125186	Coding	3	386	actgaagtggcacagtacgc	57	72
125187	Coding	3	526	gcggccggcacggccagcag	54	73
125188	Coding	3	660	ccaggctccactgctgatgc	75	74
125189	Coding	3	730	atgctgccaaacttggtctc	68	75
125190	Coding	3	735	gccggatgctgccaaacttg	79	76
125191	Coding	3	931	ggtgtgccgtccgggcccac	76	77
125192	Coding	3	984	ctagctccttgctcgggtgtg	77	78
125193	Coding	3	990	gaacctctagctccttgctcg	79	79
125194	Coding	3	1084	accagccacgcagagtgtg	83	80
125195	Coding	3	1089	gcaccaccagccacgcagag	77	81
125196	Coding	3	1193	cgccaccaccaggatgaaca	76	82
125197	Coding	3	1524	gcttggcgcccggtccttg	73	83
125198	Coding	3	1698	tggccgcgtactccaccagc	83	84
125199	Coding	3	1787	gagctgtcctcgggcggct	65	85
125200	Coding	3	2295	cgtcgggtggacgtcacggta	59	86
125201	Coding	10	2549	gtgcaaaggcagaggccgag	65	87
125202	Coding	10	2557	gtcccgtggtgcaaaggcag	78	88
125203	Coding	10	2601	aggctcagctttgggtgtgg	77	89
125204	Coding	10	2729	tcccatcttcaggtaaccgt	90	90
125205	Coding	10	2820	atatatatgtatatatacca	39	91
125206	Coding	10	3382	tctccctgectgggacacac	88	92
125207	Coding	10	3506	tgttaagtctacaacaaata	60	93
125208	Coding	10	3626	gctgccagactcaggggccc	70	94
125209	Coding	10	3729	acaaaatcgcacctgcegggt	77	95

-80-

As shown in Table 1, SEQ ID NOs 18, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 33, 35, 36, 37, 38, 39, 40, 41, 42, 45, 47, 48, 49, 50, 51, 53, 54, 55, 56, 58, 59, 60, 61, 62, 64, 66, 69, 70, 71, 72, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 5 87, 88, 89, 90, 92, 93, 94 and 95 demonstrated at least 55% inhibition of human fibroblast growth factor receptor 3 expression in this assay and are therefore preferred. The target sites to which these preferred sequences are complementary are herein referred to as "active sites" and are therefore preferred 10 sites for targeting by compounds of the present invention.

**Example 16****Western blot analysis of fibroblast growth factor receptor 3  
15 protein levels**

Western blot analysis (immunoblot analysis) is carried out using standard methods. Cells are harvested 16-20 h after oligonucleotide treatment, washed once with PBS, suspended in Laemmli buffer (100 ul/well), boiled for 5 minutes and loaded on 20 a 16% SDS-PAGE gel. Gels are run for 1.5 hours at 150 V, and transferred to membrane for western blotting. Appropriate primary antibody directed to fibroblast growth factor receptor 3 is used, with a radiolabelled or fluorescently labeled secondary antibody directed against the primary antibody species. Bands 25 are visualized using a PHOSPHORIMAGER™ (Molecular Dynamics, Sunnyvale CA).

-81-

**What is claimed is:**

5           1. A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding fibroblast growth factor receptor 3, wherein said compound specifically hybridizes with said nucleic acid molecule encoding fibroblast growth factor receptor 3 and inhibits the expression of fibroblast growth factor receptor 3.

10           2. The compound of claim 1 which is an antisense oligonucleotide.

          3. The compound of claim 2 wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO: 18, 20, 21, 15 22, 23, 24, 25, 26, 27, 28, 29, 30, 33, 35, 36, 37, 38, 39, 40, 41, 42, 45, 47, 48, 49, 50, 51, 53, 54, 55, 56, 58, 59, 60, 61, 62, 64, 66, 69, 70, 71, 72, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 92, 93, 94 or 95.

          4. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

          5. The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.

25           6. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

          7. The compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

          8. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

30           9. The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.

          10. The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

35           11. A compound 8 to 50 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of an active site on a nucleic acid molecule encoding fibroblast growth factor receptor 3.

          12. A composition comprising the compound of claim 1 and

-82-

a pharmaceutically acceptable carrier or diluent.

13. The composition of claim 12 further comprising a colloidal dispersion system.

14. The composition of claim 12 wherein the compound is  
5 an antisense oligonucleotide.

15. A method of inhibiting the expression of fibroblast growth factor receptor 3 in cells or tissues comprising contacting said cells or tissues with the compound of claim 1 so that expression of fibroblast growth factor receptor 3 is  
10 inhibited.

16. A method of treating an animal having a disease or condition associated with fibroblast growth factor receptor 3 comprising administering to said animal a therapeutically or prophylactically effective amount of the compound of claim 1 so  
15 that expression of fibroblast growth factor receptor 3 is inhibited.

17. The method of claim 16 wherein the disease or condition is a hyperproliferative disorder.

18. The method of claim 17 wherein the hyperproliferative  
20 disorder is cancer.

19. The method of claim 18 wherein the cancer is colorectal, bladder, bone, lung, cervical, breast or skin.

20. The method of claim 16 wherein the disease or condition is a developmental disorder.

25

-1-

## SEQUENCE LISTING

<110> Isis Pharmaceuticals, Inc.  
 Brett P. Monia  
 Jacqueline Wyatt

<120> ANTISENSE MODULATION OF FIBROBLAST GROWTH FACTOR RECEPTOR 3  
 EXPRESSION

<130> RTSP-0409

<150> 09/953,047

<151> 2001-09-10

<160> 95

<210> 1

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 1

tccgtcatcg ctcctcaggg

20

<210> 2

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 2

atgcattctg cccccaagga

20

<210> 3

<211> 2520

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (40)...(2460)

<400> 3

cgcgcgctgc ctgaggacgc cgcggccccc gcccccgcc atg ggc gcc cct gcc  
 Met Gly Ala Pro Ala  
 1 5

54

tgc gcc ctc gcg ctc tgc gtg gcc gtg gcc atc gtg gcc ggc gcc tcc

102

-2-

Cys	Ala	Leu	Ala	Leu	Cys	Val	Ala	Val	Ala	Ile	Val	Ala	Gly	Ala	Ser		
				10					15					20			
tcg	gag	tcc	ttg	ggg	acg	gag	cag	cgc	gtc	gtg	ggg	cga	gcg	gca	gaa	150	
Ser	Glu	Ser	Leu	Gly	Thr	Glu	Gln	Arg	Val	Val	Gly	Arg	Ala	Ala	Glu		
			25					30					35				
gtc	ccg	ggc	cca	gag	ccc	ggc	cag	cag	gag	cag	ttg	gtc	ttc	ggc	agc	198	
Val	Pro	Gly	Pro	Glu	Pro	Gly	Gln	Gln	Glu	Gln	Leu	Val	Phe	Gly	Ser		
			40				45					50					
ggg	gat	gct	gtg	gag	ctg	agc	tgt	ccc	ccg	ccc	ggg	ggg	ggg	ggg	ccc	atg	246
Gly	Asp	Ala	Val	Glu	Leu	Ser	Cys	Pro	Pro	Pro	Gly	Gly	Gly	Gly	Pro	Met	
	55					60					65						
ggg	ccc	act	gtc	tgg	gtc	aag	gat	ggc	aca	ggg	ctg	gtg	ccc	tcg	gag	294	
Gly	Pro	Thr	Val	Trp	Val	Lys	Asp	Gly	Thr	Gly	Leu	Val	Pro	Ser	Glu		
	70				75					80					85		
cgt	gtc	ctg	gtg	ggg	ccc	cag	cgg	ctg	cag	gtg	ctg	aat	gcc	tcc	cac	342	
Arg	Val	Leu	Val	Gly	Pro	Gln	Arg	Leu	Gln	Val	Leu	Asn	Ala	Ser	His		
				90					95					100			
gag	gac	tcc	ggg	gcc	tac	agc	tgc	cgg	cag	cgg	ctc	acg	cag	cgc	gta	390	
Glu	Asp	Ser	Gly	Ala	Tyr	Ser	Cys	Arg	Gln	Arg	Leu	Thr	Gln	Arg	Val		
			105					110					115				
ctg	tgc	cac	ttc	agt	gtg	cgg	gtg	aca	gac	gct	cca	tcc	tcg	gga	gat	438	
Leu	Cys	His	Phe	Ser	Val	Arg	Val	Thr	Asp	Ala	Pro	Ser	Ser	Gly	Asp		
			120				125					130					
gac	gaa	gac	ggg	gag	gac	gag	gct	gag	gac	aca	ggg	gtg	gac	aca	ggg	486	
Asp	Glu	Asp	Gly	Glu	Asp	Glu	Ala	Glu	Asp	Thr	Gly	Val	Asp	Thr	Gly		
	135					140					145						
gcc	cct	tac	tgg	aca	cgg	ccc	gag	cgg	atg	gac	aag	aag	ctg	ctg	gcc	534	
Ala	Pro	Tyr	Trp	Thr	Arg	Pro	Glu	Arg	Met	Asp	Lys	Lys	Leu	Leu	Ala		
	150				155					160					165		
gtg	ccg	gcc	gcc	aac	acc	gtc	cgc	ttc	cgc	tgc	cca	gcc	gct	ggc	aac	582	
Val	Pro	Ala	Ala	Asn	Thr	Val	Arg	Phe	Arg	Cys	Pro	Ala	Ala	Gly	Asn		
				170				175						180			
ccc	act	ccc	tcc	atc	tcc	tgg	ctg	aag	aac	ggc	agg	gag	ttc	cgc	ggc	630	
Pro	Thr	Pro	Ser	Ile	Ser	Trp	Leu	Lys	Asn	Gly	Arg	Glu	Phe	Arg	Gly		
			185					190					195				
gag	cac	cgc	att	gga	ggc	atc	aag	ctg	cgg	cat	cag	cag	tgg	agc	ctg	678	
Glu	His	Arg	Ile	Gly	Gly	Ile	Lys	Leu	Arg	His	Gln	Gln	Trp	Ser	Leu		
			200				205						210				
gtc	atg	gaa	agc	gtg	gtg	ccc	tcg	gac	cgc	ggc	aac	tac	acc	tgc	gtc	726	
Val	Met	Glu	Ser	Val	Val	Pro	Ser	Asp	Arg	Gly	Asn	Tyr	Thr	Cys	Val		
	215					220					225						
gtg	gag	aac	aag	ttt	ggc	agc	atc	cgg	cag	acg	tac	acg	ctg	gac	gtg	774	
Val	Glu	Asn	Lys	Phe	Gly	Ser	Ile	Arg	Gln	Thr	Tyr	Thr	Leu	Asp	Val		
	230				235					240					245		

-3-

ctg gag cgc tcc ccg cac cgg ccc atc ctg cag gcg ggg ctg ccg gcc	822
Leu Glu Arg Ser Pro His Arg Pro Ile Leu Gln Ala Gly Leu Pro Ala	
250 255 260	
aac cag acg gcg gtg ctg ggc agc gac gtg gag ttc cac tgc aag gtg	870
Asn Gln Thr Ala Val Leu Gly Ser Asp Val Glu Phe His Cys Lys Val	
265 270 275	
tac agt gac gca cag ccc cac atc cag tgg ctc aag cac gtg gag gtg	918
Tyr Ser Asp Ala Gln Pro His Ile Gln Trp Leu Lys His Val Glu Val	
280 285 290	
aac ggc agc aag gtg ggc ccg gac ggc aca ccc tac gtt acc gtg ctc	966
Asn Gly Ser Lys Val Gly Pro Asp Gly Thr Pro Tyr Val Thr Val Leu	
295 300 305	
aag acg gcg ggc gct aac acc acc gac aag gag cta gag gtt ctc tcc	1014
Lys Thr Ala Gly Ala Asn Thr Thr Asp Lys Glu Leu Glu Val Leu Ser	
310 315 320 325	
ttg cac aac gtc acc ttt gag gac gcc ggg gag tac acc tgc ctg gcg	1062
Leu His Asn Val Thr Phe Glu Asp Ala Gly Glu Tyr Thr Cys Leu Ala	
330 335 340	
ggc aat tct att ggg ttt tct cat cac tct gcg tgg ctg gtg gtg ctg	1110
Gly Asn Ser Ile Gly Phe Ser His His Ser Ala Trp Leu Val Val Leu	
345 350 355	
cca gcc gag gag gag ctg gtg gag gct gac gag gcg ggc agt gtg tat	1158
Pro Ala Glu Glu Glu Leu Val Glu Ala Asp Glu Ala Gly Ser Val Tyr	
360 365 370	
gca ggc atc ctc agc tac ggg gtg ggc ttc ttc ctg ttc atc ctg gtg	1206
Ala Gly Ile Leu Ser Tyr Gly Val Gly Phe Phe Leu Phe Ile Leu Val	
375 380 385	
gtg gcg gct gtg acg ctc tgc cgc ctg cgc agc ccc ccc aag aaa ggc	1254
Val Ala Ala Val Thr Leu Cys Arg Leu Arg Ser Pro Pro Lys Lys Gly	
390 395 400 405	
ctg ggc tcc ccc acc gtg cac aag atc tcc cgc ttc ccg ctc aag cga	1302
Leu Gly Ser Pro Thr Val His Lys Ile Ser Arg Phe Pro Leu Lys Arg	
410 415 420	
cag gtg tcc ctg gag tcc aac gcg tcc atg agc tcc aac aca cca ctg	1350
Gln Val Ser Leu Glu Ser Asn Ala Ser Met Ser Ser Asn Thr Pro Leu	
425 430 435	
gtg cgc atc gca agg ctg tcc tca ggg gag ggc ccc acg ctg gcc aat	1398
Val Arg Ile Ala Arg Leu Ser Ser Gly Glu Gly Pro Thr Leu Ala Asn	
440 445 450	
gtc tcc gag ctc gag ctg cct gcc gac ccc aaa tgg gag ctg tct cgg	1446
Val Ser Glu Leu Glu Leu Pro Ala Asp Pro Lys Trp Glu Leu Ser Arg	
455 460 465	
gcc cgg ctg acc ctg ggc aag ccc ctt ggg gag ggc tgc ttc ggc cag	1494
Ala Arg Leu Thr Leu Gly Lys Pro Leu Gly Glu Gly Cys Phe Gly Gln	
470 475 480 485	

-4-

gtg gtc atg gcg gag gcc atc ggc att gac aag gac cgg gcc gcc aag	1542
Val Val Met Ala Glu Ala Ile Gly Ile Asp Lys Asp Arg Ala Ala Lys	
490 495 500	
cct gtc acc gta gcc gtg aag atg ctg aaa gac gat gcc act gac aag	1590
Pro Val Thr Val Ala Val Lys Met Leu Lys Asp Asp Ala Thr Asp Lys	
505 510 515	
gac ctg tcg gac ctg gtg tct gag atg gag atg atg aag atg atc ggg	1638
Asp Leu Ser Asp Leu Val Ser Glu Met Glu Met Met Lys Met Ile Gly	
520 525 530	
aaa cac aaa aac atc atc aac ctg ctg ggc gcc tgc acg cag ggc ggg	1686
Lys His Lys Asn Ile Ile Asn Leu Leu Gly Ala Cys Thr Gln Gly Gly	
535 540 545	
ccc ctg tac gtg ctg gtg gag tac gcg gcc aag ggt aac ctg cgg gag	1734
Pro Leu Tyr Val Leu Val Glu Tyr Ala Ala Lys Gly Asn Leu Arg Glu	
550 555 560 565	
ttt ctg cgg gcg cgg cgg ccc ccg ggc ctg gac tac tcc ttc gac acc	1782
Phe Leu Arg Ala Arg Arg Pro Pro Gly Leu Asp Tyr Ser Phe Asp Thr	
570 575 580	
tgc aag ccg ccc gag gag cag ctc acc ttc aag gac ctg gtg tcc tgt	1830
Cys Lys Pro Pro Glu Glu Gln Leu Thr Phe Lys Asp Leu Val Ser Cys	
585 590 595	
gcc tac cag gtg gcc cgg ggc atg gag tac ttg gcc tcc cag aag tgc	1878
Ala Tyr Gln Val Ala Arg Gly Met Glu Tyr Leu Ala Ser Gln Lys Cys	
600 605 610	
atc cac agg gac ctg gct gcc cgc aat gtg ctg gtg acc gag gac aac	1926
Ile His Arg Asp Leu Ala Ala Arg Asn Val Leu Val Thr Glu Asp Asn	
615 620 625	
gtg atg aag atc gca gac ttc ggg ctg gcc cgg gac gtg cac aac ctc	1974
Val Met Lys Ile Ala Asp Phe Gly Leu Ala Arg Asp Val His Asn Leu	
630 635 640 645	
gac tac tac aag aag aca acc aac ggc cgg ctg ccc gtg aag tgg atg	2022
Asp Tyr Tyr Lys Lys Thr Thr Asn Gly Arg Leu Pro Val Lys Trp Met	
650 655 660	
gcg cct gag gcc ttg ttt gac cga gtc tac act cac cag agt gac gtc	2070
Ala Pro Glu Ala Leu Phe Asp Arg Val Tyr Thr His Gln Ser Asp Val	
665 670 675	
tgg tcc ttt ggg gtc ctg ctc tgg gag atc ttc acg ctg ggg ggc tcc	2118
Trp Ser Phe Gly Val Leu Leu Trp Glu Ile Phe Thr Leu Gly Gly Ser	
680 685 690	
ccg tac ccc ggc atc cct gtg gag gag ctc ttc aag ctg ctg aag gag	2166
Pro Tyr Pro Gly Ile Pro Val Glu Glu Leu Phe Lys Leu Leu Lys Glu	
695 700 705	
ggc cac cgc atg gac aag ccc gcc aac tgc aca cac gac ctg tac atg	2214
Gly His Arg Met Asp Lys Pro Ala Asn Cys Thr His Asp Leu Tyr Met	

-5-

710	715	720	725	
atc atg cgg gag tgc tgg cat gcc gcg ccc tcc cag agg ccc acc ttc				2262
Ile Met Arg Glu Cys Trp His Ala Ala Pro Ser Gln Arg Pro Thr Phe				
	730	735	740	
aag cag ctg gtg gag gac ctg gac cgt gtc ctt acc gtg acg tcc acc				2310
Lys Gln Leu Val Glu Asp Leu Asp Arg Val Leu Thr Val Thr Ser Thr				
	745	750	755	
gac gag tac ctg gac ctg tcg gcg cct ttc gag cag tac tcc ccg ggt				2358
Asp Glu Tyr Leu Asp Leu Ser Ala Pro Phe Glu Gln Tyr Ser Pro Gly				
	760	765	770	
ggc cag gac acc ccc agc tcc agc tcc tca ggg gac gac tcc gtg ttt				2406
Gly Gln Asp Thr Pro Ser Ser Ser Ser Ser Gly Asp Asp Ser Val Phe				
	775	780	785	
gcc cac gac ctg ctg ccc ccg gcc cca ccc agc agt ggg ggc tcg cgg				2454
Ala His Asp Leu Leu Pro Pro Ala Pro Pro Ser Ser Gly Gly Ser Arg				
	790	795	800	805
acg tga agggccactg gtccccaaca atgtgagggg tccctagcag ccctccctgc				2510
Thr				
tgctggtgca				2520
<210> 4				
<211> 17				
<212> DNA				
<213> Artificial Sequence				
<220>				
<223> PCR Primer				
<400> 4				
ggccatcggc attgaca				
				17
<210> 5				
<211> 21				
<212> DNA				
<213> Artificial Sequence				
<220>				
<223> PCR Primer				
<400> 5				
ggcatcgtct ttcagcatct t				
				21
<210> 6				
<211> 22				
<212> DNA				
<213> Artificial Sequence				

-6-

&lt;220&gt;

&lt;223&gt; PCR Probe

&lt;400&gt; 6

ccgccaagcc tgtcacgta gc

22

&lt;210&gt; 7

&lt;211&gt; 19

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; PCR Primer

&lt;400&gt; 7

gaaggtgaag gtcggagtc

19

&lt;210&gt; 8

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; PCR Primer

&lt;400&gt; 8

gaagatggtg atgggatttc

20

&lt;210&gt; 9

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; PCR Probe

&lt;400&gt; 9

caagcttccc gttctcagcc

20

&lt;210&gt; 10

&lt;211&gt; 3829

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;400&gt; 10

aaggatggca cagggctggt gccctcggag cgtgtcctgg tggggcccca gcggctgcag

60

- 7 -

gtgctgaatg cctcccacga ggactccggg gcctacagct gccggcagcg gctcacgcag	120
cgcgtactgt gccacttcag tgtgcggggtg acagacgctc catcctcggg agatgacgaa	180
gacggggagg acgaggctga ggacacaggt gtggacacag gggcccctta ctggacacgg	240
cccgagcggg tggacaagaa gctgctggcc gtgccggccg ccaacaccgt ccgcttccgc	300
tgcccagecg ctggcaacct cactccctcc atctcctggc tgaagaacgg cagggagttc	360
cgcggcgagc accgcattgg aggcattcaag ctgcggcatc agcagtggag cctggctcatg	420
gaaagcgtgg tgccctcgga ccgcggaac tacacctgcg tcgtggagaa caagtttggc	480
agcatccggc agacgtacac gctggacgtg ctggagcgct ccccgaccg gcccatcctg	540
caggcggggc tgccggccaa ccagacggcg gtgctgggca gcgacgtgga gttccactgc	600
aaggtgtaca gtgacgcaca gcccacatc cagtggctca agcacgtgga ggtgaatggc	660
agcaaggtgg gcccgacgg cacaccctac gttaccgtgc tcaagacggc gggcgctaac	720
accaccgaca aggagctaga ggttctctcc ttgcacaacg tcacctttga ggacgcggg	780
gagtacacct gcctggcggg caattctatt gggttttctc atcactctgc gtggctggtg	840
gtgctgccag ccgaggagga gctggtggag gctgacgagg cgggcagtgt gtatgcaggc	900
atcctcagct acgggggtgg cttcttcctg ttcacctggg tggaggcgcc tgtgaccgtc	960
tgcgcctgc gcagcccccc caagaaaggc ctgggctccc ccaccgtgca caagatctcc	1020
cgcttccgc tcaagcgaca ggtgtccctg gagtccaacg cgtccatgag ctccaacaca	1080
ccactggtgc gcacgcgaag gctgtcctca ggggagggcc ccacgctggc caatgtctcc	1140
gagctcgagc tgctgcca ccccaaattg gagctgtctc gggcccggct gacctgggc	1200
aagccccttg gggagggctg cttcgccag gtggtcatgg cggaggccat cggcattgac	1260
aaggaccggg ccgccaagcc tgtcaccgta gccgtgaaga tgctgaaaga cgatgccact	1320
gacaaggacc tgtcggacct ggtgtctgag atggagatga tgaagatgat cgggaaacac	1380
aaaaacatca tcaacctgct gggcgctgc acgcagggcg gggccctgta cgtgctggtg	1440
gagtacggg ccaagggtaa cctgcgggag tttctgcggg cgcgggcgcc cccgggacctg	1500
gactactcct tcgacacctg caagccggcc gaggagcagc tcaccttcaa ggacctggtg	1560
tcctgtgct accaggtggc ccggggcatg gactacttgg cctcccagaa gtgcatccac	1620
agggacctgg ctgcccga tgtgctggtg accgaggaca acgtgatgaa gatcgcagac	1680
ttcgggctgg cccgggacgt gcacaacctc gactactaca agaagacaac caacggccgg	1740
ctccccgtga agtggatggc gcctgaggcc ttgtttgacc gagtctacac tcaccagagt	1800
gacgtctggt cctttggggt cctgctctgg gagatcttca cgctgggggg ctccccgtac	1860

cccggcatcc ctgtggagga gctcttcaag ctgctgaagg agggccaccg catggacaag 1920  
 cccgccaact gcacacacga cctgtacatg atcatgcggg agtgctggca tgccgcgccc 1980  
 tcccagaggc ccaccttcaa gcagctggtg gaggacctgg accgtgtcct taccgtgacg 2040  
 tccaccgacg agtacctgga cctgtcggcg cctttcgagc agtactcccc ggggtggccag 2100  
 gacacccccca gctccagctc ctcaggggac gactccgtgt ttgcccacga cctgctgccc 2160  
 ccggcccccac ccagcagtgg gggctcgcgg acgtgaaggg ccactgggtcc ccaacaatgt 2220  
 gaggggtccc tagcagccca ccctgctgct ggtgcacagc cactccccgg catgagactc 2280  
 agtgcagatg gagagacagc tacacagagc tttggtctgt gtgtgtgtgt gtgcgtgtgt 2340  
 gtgtgtgtgt gcacatccgc gtgtgcctgt gtgcgtgcgc atcttgctc caggtgcaga 2400  
 ggtaccctgg gtgtccccgc tgctgtgcaa cggctcctg actgggtgctg cagcaccgag 2460  
 gggcctttgt tctgggggga ccagtgacg aatgtaagtg ggcccaccg gtgggacccc 2520  
 gtggggcagg gagctgggcc cgacatggct cggcctctgc ctttgacca cgggacatca 2580  
 cagggtgccg tcggcccctc ccacacccaa agctgagcct gcagggaagc cccacatgtc 2640  
 cagcaccttg tgctgggggt gttagtggca ccgcctcccc acctccaggc tttcccactt 2700  
 cccaccctgc ccctcagaga ctgaaattac gggtagctga agatgggagc ctttaccttt 2760  
 tatgcaaaag gtttattccg gaaactagtg tacatttcta taaatagatg ctgtgtatat 2820  
 ggtatatata catatatata tataacatat atggaagagg aaaaggctgg tacaacggag 2880  
 gcctgcgacc ctggggggcac aggaggcagg catggccctg ggcggggcgt gggggggcgt 2940  
 ggaggagggc ccagggggtc tcacccatgc aagcagagga ccagggcttt ttctggcacc 3000  
 gcagttttgt tttaaaactg gacctgtata tttgtaaagc tatttatggg ccctggcac 3060  
 tcttgttccc acaccccaac acttccagca ttagctggc cacatggcgg agagttttaa 3120  
 tttttaactt attgacaacc gagaaggttt atcccgcga tagagggacg gccaagaatg 3180  
 tacgtccagc ctgccccgga gctggaggat ccctccaag cctaaaagg tgttaatagt 3240  
 tggaggatgat tccagtgaag atattttatt tgctttgtcc tttttcagga gaattagatt 3300  
 tctataggat ttttctttag gagatttatt ttttgactt caaagcaagc tggatatttc 3360  
 atacaaatc ttctaattgc tgttgttccc aggcaggag acggtttcca gggaggggccc 3420  
 ggccctgtgt gcaggttccg atgttattag atgttacaag tttatatata tctatatata 3480  
 taatttattg agtttttaca agatgtattt gttgtagact taacacttct tacgcaatgc 3540  
 ttctagagtt ttatagcctg gactgctacc tttcaaagct tggagggaag ccgtgaattc 3600

- 9 -

```
agttgggttcg ttctgtactg ttactggggc ctgagctctgg gcagctgtcc cttgcttgcc 3660
tgcagggcca tggctcaggg tggctctcttc ttggggccca gtgcatgggtg gccagaggtg 3720
tcacccaaac cggcaggtgc gatTTTgtta acccagcgac gaactttccg aaaaataaag 3780
acacctgggtt gctaacctga aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 3829
```

<210> 11  
<211> 924  
<212> DNA  
<213> Homo sapiens

<220>

<221> unsure  
<222> 414  
<223> unknown

<221> unsure  
<222> 415  
<223> unknown

<221> unsure  
<222> 416  
<223> unknown

<221> unsure  
<222> 417  
<223> unknown

<221> unsure  
<222> 418  
<223> unknown

<221> unsure  
<222> 419  
<223> unknown

<221> unsure  
<222> 420  
<223> unknown

<221> unsure  
<222> 421  
<223> unknown

<221> unsure  
<222> 422  
<223> unknown

<221> unsure  
<222> 423  
<223> unknown

<221> unsure  
<222> 424  
<223> unknown

<221> unsure  
<222> 425  
<223> unknown

<221> unsure  
<222> 426  
<223> unknown

<221> unsure  
<222> 427  
<223> unknown

<221> unsure  
<222> 428  
<223> unknown

<221> unsure  
<222> 429  
<223> unknown

<221> unsure  
<222> 430  
<223> unknown

<221> unsure  
<222> 431  
<223> unknown

<221> unsure  
<222> 432  
<223> unknown

<221> unsure  
<222> 433  
<223> unknown

<221> unsure  
<222> 434  
<223> unknown

<221> unsure  
<222> 435  
<223> unknown

<221> unsure  
<222> 436  
<223> unknown

<221> unsure  
<222> 437  
<223> unknown

<221> unsure  
<222> 438  
<223> unknown

<221> unsure  
<222> 439

- 11 -

&lt;223&gt; unknown

&lt;221&gt; unsure

&lt;222&gt; 440

&lt;223&gt; unknown

&lt;221&gt; unsure

&lt;222&gt; 441

&lt;223&gt; unknown

&lt;221&gt; unsure

&lt;222&gt; 442

&lt;223&gt; unknown

&lt;221&gt; unsure

&lt;222&gt; 443

&lt;223&gt; unknown

&lt;221&gt; unsure

&lt;222&gt; 444

&lt;223&gt; unknown

&lt;221&gt; unsure

&lt;222&gt; 445

&lt;223&gt; unknown

&lt;221&gt; unsure

&lt;222&gt; 446

&lt;223&gt; unknown

&lt;221&gt; unsure

&lt;222&gt; 447

&lt;223&gt; unknown

&lt;221&gt; unsure

&lt;222&gt; 448

&lt;223&gt; unknown

&lt;221&gt; unsure

&lt;222&gt; 449

&lt;223&gt; unknown

&lt;221&gt; unsure

&lt;222&gt; 450

&lt;223&gt; unknown

&lt;221&gt; unsure

&lt;222&gt; 451

&lt;223&gt; unknown

&lt;221&gt; unsure

&lt;222&gt; 452

&lt;223&gt; unknown

&lt;221&gt; unsure

&lt;222&gt; 453

&lt;223&gt; unknown

&lt;221&gt; unsure

-12-

<222> 454  
<223> unknown

<221> unsure  
<222> 455  
<223> unknown

<221> unsure  
<222> 456  
<223> unknown

<221> unsure  
<222> 457  
<223> unknown

<221> unsure  
<222> 458  
<223> unknown

<221> unsure  
<222> 459  
<223> unknown

<221> unsure  
<222> 460  
<223> unknown

<221> unsure  
<222> 461  
<223> unknown

<221> unsure  
<222> 462  
<223> unknown

<221> unsure  
<222> 463  
<223> unknown

<221> unsure  
<222> 464  
<223> unknown

<221> unsure  
<222> 465  
<223> unknown

<221> unsure  
<222> 466  
<223> unknown

<221> unsure  
<222> 467  
<223> unknown

<221> unsure  
<222> 468  
<223> unknown

-13-

<221> unsure  
<222> 469  
<223> unknown

<221> unsure  
<222> 470  
<223> unknown

<221> unsure  
<222> 471  
<223> unknown

<221> unsure  
<222> 472  
<223> unknown

<221> unsure  
<222> 473  
<223> unknown

<221> unsure  
<222> 474  
<223> unknown

<221> unsure  
<222> 475  
<223> unknown

<221> unsure  
<222> 476  
<223> unknown

<221> unsure  
<222> 477  
<223> unknown

<221> unsure  
<222> 478  
<223> unknown

<221> unsure  
<222> 479  
<223> unknown

<221> unsure  
<222> 480  
<223> unknown

<223>

<400> 11  
ggacacaggt gtggacacag gtaggagcag ggtccagggc tcaggccagc cgggggtgggg 60  
cccgtgccca ccgccaagcc ctgcccttca caggcaggtg agggactaag ggcccgggaac 120  
aacctccctg gggtcacccc gaaggtcttg tccctcaggg atacaggagg ggctgggtca 180

-14-

```

ctgacatggc tctagatgcc ccaccctggt ggcagggctg gtgtgcaagg ggactccgtg 240
ttgctgatgg ggagactgag gcacagggcc ctgggggttc caggagcagg aggaggccag 300
ggctggcctg tggggctctg gtgttggtta taggtgaggt ggaccccgca gacattagcg 360
cagcagggca gggcactcag gtggctgccg tggggtggat ggacccgggg tgannnnnnn 420
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 480
caactccctc caagactcct ggctctcaag cgactgggct cctctcctgg taacttctcc 540
caggtcctgc cttgtccact agatggcctc cccctcgggt cttcagtctc ccggttggtg 600
ggcctgtccc tgtcacaccc ctctgggcag gtgggctccc ctggacaatg ccctgtgccc 660
tgtgacttca caggtccggg cagagcaccc tggaggggag gggaggggac acacggccca 720
gctctgagaa agccccgggg aggggacaag atgtggaggc tcctgggaac ctcatcccgc 780
cctcttctta cacaggacgg gaaactgagg ctggggatgg gcaggggcag ctctgggaag 840
ggggttggtc agaggggcct ctgctccac tcgggtcatg gccttcacac gcacctcggc 900
ccgcaggggc cccttactgg acac 924

```

&lt;210&gt; 12

&lt;211&gt; 940

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; 639

&lt;223&gt; unknown

&lt;223&gt;

&lt;400&gt; 12

```

cccggacggc acaccctacg ttaccgtgct caaggtgggc caccgtgtgc acgtgggtgc 60
cgccgctggg gctcctgggc tggccccaag ggtgccctt ggctgcgggt tgcgtgagga 120
tttgatctta ggggttgagg cttcgggggc agaagctgtg ggggtgcttg tggggccaag 180
tctcagccac ccacacctc agggccatag gcagctgcgt tgggaccctg ttccgtgtct 240
gcagagggcc agcctcagcc actgaagtcc ctgacatgga gctgccacg ggcttcttgg 300
gggtgggtgc ggtttgggca gcagtgggtc ccaggacag gagggcagtg tggccaagcc 360
ctccaggccc cctcttggcc tcagaggcgg tgggtgagcc ccgacctggc cgattgggtc 420
tcgtcagctg tgtgcagtgg ggcccagact cactgtctgc ccgcctctg aagcccttag 480

```

-15-

```

ctttgttccc attgctgccg ggtggggggcc actgaattgg gacggttgcg acactcaaag   540
cccaaagaga aacatctgtt cagagagaag acggtctctt gggggcgggg agcaggcgca   600
gggcgagggt ggagtccaga ccccgcccag agaggccgnc tcggggccctg tccagggtgc   660
aggttctgca agagcccggg ggagggcagg ccagtgacca gaggttgtgt gagggctctgg   720
gctgggttgt tggggtgagg gcagagacgt tcacctctgt aaaccacagc caccgtgaag   780
tgactccacg actcctccag gcagcctttg gggctgacgc agcccagcct cgatctgtac   840
cttgggggtc tccacatcc tgccctctgc ccggcggggt gcctcggggg cgtgcttgag   900
ccgggtctct tgtccccga gtccctggatc agtgagagtg                               940

```

&lt;210&gt; 13

&lt;211&gt; 662

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;400&gt; 13

```

ggccccgagc aggtaacgac tctgtcccat gccggccggc acaagagctc cagctccaag   60
gccctggccg cgcgccttgc acgccccgca cggcccagcc ctgctcgctc ccgccccggc   120
tcgcgtccca ctgggggccc cctcggcaag gctggcagct ccagcctcca cggtgaccgc   180
ccgcttcgag cctgtggcc tgcgcgacc cttcccgcac gcctgcgacc cccacaggag   240
gtgcccgggtg cccaccgggc cggctccgtg ccgtctgtga gcacccttt gcgcctctct   300
ccacccttgc ccgctgcctg ctgcgttccg cagcctgtgt gtaccctgtg tccatcctcc   360
acctgcaccc gcccggtctt gcgctaacct gcatgctgcc tgcccgcctg ccgctcacct   420
gggacagagg actcgccggt ggagggggcct ggcttcgggc tcagtaccgg tgtaccaggc   480
ggagggccct caaccgctg gcggtgacca agttgacgat ggctgaggag ttggtggtgg   540
cggcgttttc cttgcagcgg ctggatcctg ccgtgtggac tctgtgcggt gcccgcaggg   600
cggtgctggc gctcgctat cgtctgctc tctctttgta gacggcgggc gctaacacca   660
cc                                                                                   662

```

&lt;210&gt; 14

&lt;211&gt; 343

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

-16-

<400> 14  
 ttcccgcctca agcgacaggt aacagaaagt agataccagg ttctgagctg cctgcccgcc 60  
 aggccctcctg gagccccacc tcggggccacg ctgggtcctgg gctgtgtgag ccctctctgc 120  
 agccaggcgg gctccccctct cctcgtctct gctcaccatg tagagcctag ggtactttgg 180  
 ggacacgaaac attctaaaaa tcttcattca atgctgggtgg aagtcagaac gccccccctt 240  
 ctggcccagc actgaccccc ggctgtacct ccacgccctg tcgcccacgc ggcgccaacc 300  
 tgccccctgct gacccaagca ggtgtccctg gagtccaacg cgt 343

<210> 15  
 <211> 248  
 <212> DNA  
 <213> Homo sapiens

&lt;220&gt;

<400> 15  
 cactcaccag agtgacgtgt acgtgtcctg cagagctcag gcttcagggg tggaggcggg 60  
 aactgggcag agccaggacc ccagctgcag tccccaggcc tgtgccctgg agctcctggg 120  
 tgtggtttct acccctccct gggggcagca gcgcagacct ggcctattac ccctggtgcc 180  
 cgcccagggtg tctgtcctgg gagtctcagg acagcctgac ctcaccttcc cctgtagctg 240  
 gtcctttg 248

<210> 16  
 <211> 171  
 <212> DNA  
 <213> Homo sapiens

&lt;220&gt;

<400> 16  
 tgcacacacg acctgtgagt ggcatccctg accctccact gggtcctcag ggggtggggat 60  
 ccctccgggg ctgggcgggg gagggactgg cagcccttca ggctgttccc gaataaggcg 120  
 ggaagcggcg ggactcactc ctgagcgccc tgcccgcagg tacatgatca t 171

<210> 17  
 <211> 5233  
 <212> DNA  
 <213> Homo sapiens

&lt;220&gt;

&lt;400&gt; 17

-17-

ggcgagcggc	aggtaagaag	ggaccacta	ggcacgggag	aggccggccc	gtgcgggcag	60
aggcgttggg	gacgggaacc	ggccccgggt	cggagggggc	gccgggtgtg	agtgcgccc	120
cggggttaga	gcccggttc	cgtgcctcc	ttgccggaga	gcgcggccag	agctagcgcg	180
gcgacttgtg	gtgcgcccgg	agccgcagct	accctccaag	tgcgaggcca	ccacggggag	240
ccaggctggg	ggttggcgtc	cgcagccccg	atccccctgcg	actccctagc	cctggcctgt	300
cgggagggcg	cggggggccc	catttccacg	attcccgcgtg	ttgttattcg	ggttctgcgc	360
agacggaaag	ttcccattgt	tggcgtcccc	ctcccccggg	ccccagtttg	tggccagctt	420
cagccaaggc	gagagaccgg	acttctaagg	gtgggtgtgc	gcgtcagcga	agcccgggcc	480
ctgccccccc	gaagaggcag	cagcctccag	cgtccccgct	gccgacctg	cccctgcctg	540
ggggccgagg	gcgcttcccc	gtgggtgcgc	gccgagctcc	aggcaagcga	ggggcgcgctg	600
tcccagcgtc	gcggggcccta	gactgggctg	gcggtccagg	tccgcgggga	cgtcgaggggt	660
ctgaagggag	gtcccaaggg	gcgaggggag	gggaaggggc	gcccggccgg	acctgcacac	720
gcgccgcggt	tcctcgtggg	ccgggcccag	agctccgggtg	ccgccgccgc	gtacaccgcg	780
tgcggctcc	ggacgggcga	ggggggcgcg	cacagctcag	cccggcgggc	gcgcggaggg	840
aggccttggc	ccggtgagct	cgcgccccac	ccgggcccag	gcccgaacag	ccgcttcttt	900
gtacctcgac	gcggccacag	accgcgcatt	gatggcggt	cggcggtctg	cggggaggtg	960
tgagcgaccg	cgggcgcggc	gggcccggga	gggcgcctgg	agggccgagg	cagatggcgt	1020
ccgccccgcc	cgcgcccccg	cgcccccttc	tccgtcggcg	gctgcagcct	cccggaaaca	1080
tgtcattttt	tttatgaatg	aaagtggccc	ggcgcttgaa	tgtgcgtgtc	attcagcggc	1140
gtgacagggg	ccgtcgggag	gtcagcgcg	gcttttagcg	tctgctcggg	cggccccgct	1200
tccaggggtg	ccggaggggc	ggccgcgggg	ggagcttggc	tttcgcattc	tcattcagat	1260
aaagatatta	ctccctacgg	cccgggaatg	tcagccagcc	ccggggaagg	gcggcgccca	1320
ggctgcggag	cctctcctgg	acccccctgcg	ggcgcgcggg	gcctccccca	gtcgctcctg	1380
gaacgccccg	cccaccctc	ccccggggcg	gcgccccgc	ccgcactgga	gctggtgaaa	1440
caggtagtga	gttgatcggt	caataaactt	aatccggttc	cttaacaaga	tgggcccggc	1500
agtaaaaata	caaagacctc	gtgaaatgga	ctgaggtcta	ggctggcgct	tgcccgggaa	1560
cataaattat	ggagccttgg	ctcgcagggg	tcaagggcgg	tgggaaagg	tttggccact	1620
ggactgccct	ggccacccca	ggccctgcc	ggacagcccc	catctcccca	gggggcccgt	1680
ttcctgggtg	ggacctggag	tgacccccca	gggtgcaggg	aggtagacaa	ggtcggtctt	1740
cccacagtcc	cacccaccc	agcaggggtc	tgggggtgca	gggcctttcc	cgaaggtgct	1800

ggctgcaacc tcccccactc ctctcttgca gggctggact ttgagccgcg tgggcctctg 1860  
ggtggttcat taacctgggc tgagcctggc ctccaggtec ttgtgtgagc ctaggaaccc 1920  
cttgttaccc acccccagc tccccagccc tcagggtctca cttggggcta gatctggggc 1980  
tgcggcaccc cttgttacag ctgagcttga gtgggagccc aggggcttgg ggtctcctgg 2040  
aggacgggga tctaaagtca cctcatctag ggaggcatgc agccctcacc tgaatgattc 2100  
aggagtgaat gagccaggag tggagccacc tttggtgggg taggggtcag cctggacctc 2160  
taggctgcca gctcaggctc gggcgccctc ttggaacctc agtttcctta cctgtccaag 2220  
agaaccgata atggcaggct gtttgaagga ttaggccaga taaccctggc aagccctctt 2280  
tagcctgccc agcctccaga tccctttttt ccggaactta ttgtgaaact ccagggtgggg 2340  
agacagggag gctggacttt tgggggcccc ctctctcttag gctattttat agctcctacc 2400  
tggcaatacc tctgtaccc cagagagctg cagagaactt catgtgcac cgaaccaga 2460  
atgtgttgtt tctgacccc aggcctcat ctaccccaa aacccaaata aaccctggg 2520  
gcagccagct ccggaagcga gtctggattt gatccttgtt ctctggggtc aaccgaggg 2580  
gcttatgatg gagcaaggct ccccatcct ctacagccatg ctccctcaca tgcaactgggc 2640  
ctccactgca gagaccaga gcctggagaa aggttcccca ggccagagtt tggccgtccc 2700  
cagcaccctg cctaattggac atcagtcttg gggccagaga ccagggcag ggagcgctc 2760  
tcaccctac cctcactcct gcagccattt cagggcctgg tgccctcct gagctcctgg 2820  
gcctgtgggg tgggattttt actttgtgcc acagtggggg aaactgaggt acaggaccag 2880  
tgagtggcag agttgtggag actctgggac acagcagagg gctgtcgttg gcatgtggag 2940  
cccaagttga ggtcggcact gtgtgggggt gggcgccgg caggagcacg tgttgtggga 3000  
tccatagaag ggtgggaggt gggacgcgtt gcctcctacc ccgccttggg tacagcagga 3060  
gttttgtctc caacgtgtt gggcaccagt gtctgtgtgg tgtcagtggg gcctcccttt 3120  
tgtggatcaa gaaagaaaga acccttcta gggctgctgg ggggctatag ctctcccat 3180  
gcctggcagc tgggtggggt atgggggctc caccctactg ctgacttccc agtgggagtc 3240  
agaccctgaa cttatagcac ccaactcatgc ccggtgtcac actgtccttc acctggtgct 3300  
cgccaccag cccctgctgg ggtaccctgg cctctgctgg cacctagcag gcaggcagtg 3360  
gggggggcag tcagggtgct accctccca ccacacacgg gcagatggcc actggtgtgg 3420  
ctggcctggg gctgctgtgt ccccgctccc ccggtgctgg accaggctga agcaaatact 3480  
tgtgtggatg gcttgacctg ttgtgccac tcagaccaa ccggaacca ccggctgttg 3540

-19-

```

cccttggggcc agggcctgca gctgaggctg ccataaccag cctgttctcg gccttctggg 3600
gggcctcgag cagctcccag ctctgggtgg tccccacaag aactggcca ggaccggagg 3660
gctggaggtc aggccaggag cccccctgac tgcgggggtcc ctacaggggc agtccttgag 3720
ctgtgggtcc ctgtggggcg agggctcctt cggatgcttc aggggatgag tgtggggcct 3780
tctggctggc agggtcaccc tgggcactag gcgtgtgtgg ctggatcagg tgggttgggc 3840
agaagagggc ctggccgggc agccaggagc tgggtgtggc agagtgggca gctgggcccc 3900
cgaatctagg ccacgcgtct gcagaatgac aagtgatggc gcaaccgcc cagctgggtc 3960
tgaagaagga ggctgcctgg gggaccaccc acccccgctc cggccccaaag cccgggacgc 4020
ctgcctgcat gcattgtctg gccctggcag ggaagcctag gggcgattgt cccccagcc 4080
ctgcccattg tgtgtccttg ggtcacaggc tttggtggct ctggggagct gggcagctac 4140
tggggaggga cccaggggcc acctgcacat ctgcccctgt ggggtgggcc ccacccagc 4200
ttctcagccc ccaggagggg gccagggctg ctgacctgcc ctggctctca cagcttctg 4260
ccccagcct ggtcgtcctc tgtgaggggg cccagtccc ccctgcaggc agcaggactc 4320
cacccccggg ccccttgag gggccgctg ggctcccca ctccccggc tgtgagacc 4380
acttgccgg acccagcgc gtgtttgtac tttgtctctc tcggtatgtt ttccgtcatg 4440
accgccgtgt ggagcttcca taggagctgc aggatacaga acctgcca cccaaggag 4500
ccccacccc cggcccgcc ccctcgctg gctccggcct gtgctctgac cggatgaacc 4560
gcgcatcgcc cccagaccg tccacacggc cacgtgacc tgcacctct tccttctcgc 4620
ctgttctgtt ccctggctgt ccatctgaac tgcttttcag gctcatatgg ggtgcggggg 4680
ctactgagga cggacccctc ctggggtgaa tctgcaccac gagggggctg gctggccaac 4740
cctggcacc ctctgagctc catttcagtc agaggccagc aaagggcagc ctgtcccctt 4800
tgcccgcagc acctgcccgt cgtggtgccg cctgtgagac aagcatggat tttatgtttc 4860
caagcaattg aacaaattaa aagaacgaag agtcacattt tgtgacactt tgagatttga 4920
attctccgtg tccatgagtg aagcatcatg gggccactgc tgtgggggtg gctgcaggtt 4980
gtgtggggaa ggcggctgtc acaccgaggc agaccggagt ccttgggaca gactgggttg 5040
caaagctgaa gatagagacc tttggccctt ttgggacaca gtttccagcc cctggctctg 5100
tgggaccctg gatctgggtc agagccttcc tcactcaggg ccgccgaggc ttccactgct 5160
gtgtctgtaa acggtgccgg gtttgggggt gcctgcctca tgggtgcca tcttcccac 5220
agaagtcccc ggc 5233

```

-20-

<210> 18  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 18  
gcggcgctcct caggcagcgc

20

<210> 19  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 19  
gaggcgccgg ccacgatggc

20

<210> 20  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 20  
cgcacactga agtggcacag

20

<210> 21  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 21  
tcccgaggat ggagcgtctg

20

<210> 22  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

-21-

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 22

cttcgtcatc tcccaggat

20

&lt;210&gt; 23

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 23

gtccacacct gtgtcctcag

20

&lt;210&gt; 24

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 24

ccgctcgggc cgtgtccagt

20

&lt;210&gt; 25

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 25

cttcagccag gagatggagg

20

&lt;210&gt; 26

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 26

gcgtgtacgt ctgccggatg

20

&lt;210&gt; 27

-22-

<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 27  
cttgcaagtgg aactccacgt 20

<210> 28  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 28  
gccacattg ctgccgttca 20

<210> 29  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 29  
ccccgtagct gaggatgcct 20

<210> 30  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 30  
acctgtcgct tgagcgggaa 20

<210> 31  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

-23-

<400> 31  
aggagtagtc caggcccggg 20

<210> 32  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 32  
gttgtgcacg tcccggggcca 20

<210> 33  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 33  
gtggcccttc acgtccgcga 20

<210> 34  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 34  
gggacccctc acattgttgg 20

<210> 35  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 35  
acgcggatgt gcacacacac 20

<210> 36  
<211> 20

-24-

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 36

cccagaacaa aggccctcg

20

&lt;210&gt; 37

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 37

ccgagccatg tcgggccag

20

&lt;210&gt; 38

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 38

agcgcaccct gtgatgtccc

20

&lt;210&gt; 39

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 39

tacacagcat ctatttatag

20

&lt;210&gt; 40

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

-25-

<400> 40  
taccagcctt ttcctcttcc 20

<210> 41  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 41  
gtcgcaggcc tccgttgtag 20

<210> 42  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 42  
cctgtgcccc cagggtcgca 20

<210> 43  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 43  
gggcccataa atagctttac 20

<210> 44  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 44  
ggttgtagcaat aagttaaaaa 20

<210> 45  
<211> 20  
<212> DNA

-26-

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 45

cttggccgtc cctctatcgg

20

&lt;210&gt; 46

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 46

aaaatatctt cactggaatc

20

&lt;210&gt; 47

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 47

tctcctgaaa aaggacaaag

20

&lt;210&gt; 48

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 48

atttgatatga aaataccagc

20

&lt;210&gt; 49

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 49

-27-

cctgggacac acagcaatta 20

<210> 50  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 50  
catcggaacc tgcacacagg 20

<210> 51  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 51  
tccaagcttt gaaaggtagc 20

<210> 52  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 52  
atggccctgc aggcaagcaa 20

<210> 53  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 53  
accatgcact gggccccaag 20

<210> 54  
<211> 20  
<212> DNA  
<213> Artificial Sequence

-28-

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 54

aggtgtcttt atttttcgga

20

&lt;210&gt; 55

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 55

gtagcaacc aggtgtcttt

20

&lt;210&gt; 56

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 56

tgaccctgc tcctacctgt

20

&lt;210&gt; 57

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 57

ggagcagagg cccctctgaa

20

&lt;210&gt; 58

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 58

gcttgccac actgccctcc

20

-29-

<210> 59  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 59  
acagatgttt ctctttgggc 20

<210> 60  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 60  
gcccccaaga gaccgtcttc 20

<210> 61  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 61  
gcgggttagc gcagagccgg 20

<210> 62  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 62  
cacggcagga tccagccgct 20

<210> 63  
<211> 20  
<212> DNA  
<213> Artificial Sequence

-30-

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 63

gctccaggag gcctggcggg

20

&lt;210&gt; 64

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 64

aggtgaggtc aggctgtcct

20

&lt;210&gt; 65

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 65

agggatgccca ctcacaggtc

20

&lt;210&gt; 66

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 66

cgccgggctg agctgtgcgc

20

&lt;210&gt; 67

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 67

ccgcgtcgag gtacaaagaa

20

-31-

<210> 68  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 68  
ggagacccca agcccctggg 20

<210> 69  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 69  
cctcgggttg accccagaga 20

<210> 70  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 70  
gtgaccctgc cagccagaag 20

<210> 71  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 71  
cagtacgcgc tgcgtgagcc 20

<210> 72  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

-32-

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 72

actgaagtgg cacagtacgc

20

&lt;210&gt; 73

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 73

gcggccggca cggccagcag

20

&lt;210&gt; 74

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 74

ccaggctcca ctgctgatgc

20

&lt;210&gt; 75

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 75

atgctgccaa acttggttctc

20

&lt;210&gt; 76

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 76

gccgatgct gccaaacttg

20

-33-

<210> 77  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 77  
ggtgtgccgt ccgggccac 20

<210> 78  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 78  
ctagctcctt gtcggtggtg 20

<210> 79  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 79  
gaacctctag ctccttgctg 20

<210> 80  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 80  
accagccacg cagagtgatg 20

<210> 81  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

-34-

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 81

gcaccaccag ccacgcagag

20

&lt;210&gt; 82

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 82

cgccaccacc aggatgaaca

20

&lt;210&gt; 83

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 83

gcttggcggc ccggtccttg

20

&lt;210&gt; 84

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 84

tggccgcgta ctccaccagc

20

&lt;210&gt; 85

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 85

gagctgctcc tcgggcggct

20

&lt;210&gt; 86

-35-

<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 86  
cgtcggtgga cgtcacggtgta 20

<210> 87  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 87  
gtgcaaaggc agaggccgag 20

<210> 88  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 88  
gtcccgtggt gcaaaggcag 20

<210> 89  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 89  
aggctcagct ttgggtgtgg 20

<210> 90  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

-36-

<400> 90  
tcccatcttc aggtaccgt 20

<210> 91  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 91  
atatatatgt atatatacca 20

<210> 92  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 92  
tctccctgcc tgggacacac 20

<210> 93  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 93  
tgttaagtct acaacaaata 20

<210> 94  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 94  
gctgcccaga ctcagggcc 20

<210> 95  
<211> 20

-37-

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 95

acaaaatcgc acctgccggt

20